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1. Introduction 
 
1.1 Sudden death during change of treatment of pulmonary 
arterial hypertension – the case history that started the project 
 
During my pediatric cardiology trainee period, I was engaged in the treatment of a baby 
girl with a large primum ASD, presenting at 8 months, with crying spells leading to near 
syncope. She had poor feeding and weight gain, increased sweating, reduced activity and 
pulmonary artery pressures at systemic level. Eight weeks of oral sildenafil brought some 
symptomatic improvement but no reduction of tricuspid regurgitation peak jet velocity. 
Intravenous epoprostenol was started, replacing the insufficient sildenafil treatment. Lack 
of experience with combination therapy made this an unpredictable option. She was 
continuously monitored by ECG, SpO2 plus frequent registration of vital signs. During 
the uptitrating of epoprostenol, she became more irritable and had slight desaturation 
during crying, accompanied twice by short bradycardias. She died suddenly on day four, 
when awake, just after the observing nurse had commented that her vitality was 
improving. There was no response to advanced heart-lung resuscitation. An exact death 
mechanism could not be established. The question was what mechanism of hemodynamic 
deterioration that had occurred without being detected by our monitoring tools. Based on 
history, blood tests, radiograms and autopsy findings, we concluded lung congestion with 
microatelectasis could have induced ventilation-perfusion mismatch following 
epoprostenol infusion, producing desaturations that she did not tolerate in a situation with 
low cardiac output. Rebound PAH crisis due to the termination of oral sildenafil was 
considered less probable, as it had been replaced by a very potent drug, although with a 
different mechanism of action. Reviewing possible mechanisms of sudden, unexpected 
death during change of pulmonary vasodilator drugs in this infant with ASD primum and 
out of proportion pulmonary hypertension, we concluded that improved monitoring 
options in patients with severe PAH-CSPS are required(1).  
This sad case history increased my respect for, and interest in the PAH diseases, and it 
also draws a thematic line through the present thesis: 
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The search for monitoring parameters and disease markers in acute and chronic 
PAH-CSPS 
Valid and reliable biomarkers and endpoints in studies of pediatric PAH are highly 
requested(2). The European Society of Cardiology list of gaps of PH evidence mentions 
disease assessment as one of the main topics (www.escardio.org). The present thesis 
provides a review of current knowledge about PAH-CSPS monitoring tools, integrating 
the experiences from the five published papers. 
 
1.2 The pulmonary circulation in pediatric cardiology 
 
The normal, four-chambered heart serves two vascular circuits that normally become 
separate when the fetal shunts close after birth. When the neonatal adaptation is 
complete, these two vascular beds have striking differences regarding the nature of their 
pumping chambers, the pressure levels and resistances, vasoregulatory mechanisms, and 
the drugs that modify these. In adult cardiology, much attention has been directed to the 
systemic circulation and the left ventricle, in conditions like atherosclerosis and systemic 
arterial hypertension. In pediatric cardiology, on the contrary, pulmonary hemodynamics 
is an important part of the background for decision making, in a wide range of clinical 
situations. Postnatal pulmonary vascular adaptation is an important issue in almost all 
newborns with congenital heart disease. 
 
1.2.1 The significance of pulmonary vascular disease in children with 
congenital systemic to pulmonary shunts 
 
The most common congenital heart defects, the systemic to pulmonary shunts, such as, 
VSD, PDA and also ASD may produce pulmonary arterial hypertension if they are not 
repaired in time. Patients with these diagnoses are the focus of this thesis. Based on 
hemodynamic characteristics, these shunts can be divided into pretricuspid (ie ASD and 
P/TAPVC) and post-tricuspid (VSD, PDA, AP-window). The blood flow and pressure 
transmitted trough such a defect, stretch the pulmonary vessel walls. These stretch stimuli 
induce vasoconstriction and subsequently, vascular wall thickening and lumen narrowing 
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(3;4). (Further details in chapter 1.3.1) At first, these are reversible changes, but a 
continued stimulus leads to irreversible PAH with time in many patients, but not in all. 
Genetic susceptibility for vascular changes probably plays a role, but predisposing 
mutations with effect on cell growth control have only been documented in a few  
patients(5). Granton et al found that 50 % of patients with a large VSD,10 % of patients 
with ASD, as compared to 100 % of patients with truncus arteriosus will develop PAH if 
left untreated (6). In some patients with small or pre-tricuspid shunts, as in paper I, the 
increased flow stimulus is only a trigger of disease development, while PAH 
development seems to be out of proportion and driven by other mechanisms (7;8). 
Children with Down syndrome are, for reasons incompletely understood, predisposed to 
faster and more frequent development of irreversible PAH than non-Down patients(9).  
Without repair, the majority of patients with non-restrictive VSD develop increasing 
pulmonary vascular resistance due to wall changes, and finally reversal of the shunt. This 
condition is called Eisenmenger’s syndrome. Patients with Eisenmenger’s syndrome and  
simple cardiac lesions, such as ASD, VSD, PDA have a life expectancy reduction of 
about 20 years(10). Life quality is also affected by severely reduced physical 
performance. Serious complications occur frequently, like brain abscess or 
thromboembolic disease. (10;11). Only 15 years ago, patients with CSPS were generally 
operated at a higher age than today. Consequently, pulmonary vascular disease was 
established at the time of operation in many cases, and postoperative pulmonary 
hypertensive crises were not infrequent. With further development of surgery, anesthesia 
and heart-lung-machine technology, operations could be performed earlier, leaving less 
time for preoperative pulmonary vascular injury. Further, the introduction of inhaled 
nitric oxide has made patients with acute postoperative PH easier to handle, making death 
from PH rare in this setting. A few studies on the reversibility of vascular changes and 
timing of operation have set the standards for the current policy of timing for defect 
closure(12;13). The current clinical standard is to repair large, non-restrictive defects 
between 3 and 12 months of age, depending on control of heart failure (14). Earlier 
operations are undertaken in children with failure to thrive despite maximal drug 
treatment and in patients with risk factors, such as Down syndrome. The risk of 
permanent pulmonary vascular injury increases with age at operation. Closure of a non-
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restrictive posttricuspid defect after 1 year of age, carries a higher risk of postoperative 
acute pulmonary hypertensive crises and irreversible PAH. The point of no return 
(irreversible disease), at which surgery is detrimental, probably differs with genetic 
predisposition. Some patients tolerate pulmonary vascular wall stress for a longer time. 
This difference is incompletely investigated.  
So – is PAH of any significance in modern pediatric cardiology? Yes, the PAH-CSPS 
patients still occur, and some data indicate a higher prevalence than previously 
recognized at long term follow up(15). Even more frequent subclinical disease has been 
suggested(16). 
 
1.2.2 Definitions 
 
Pulmonary vascular (obstructive) disease is a histopathological term, and denotes any 
degree and permanency of thickening of the pulmonary vascular walls, distorted vascular 
structure and reduced number of small vessels, leading to intermittently or permanently 
increased pulmonary vascular resistance. It is a useful term in congenital heart disease, 
because some patients have no pulmonary pumping chamber (Fontan circulation) and 
low pulmonary artery pressures, but still a too high pulmonary vascular resistance. 
Pulmonary hypertension is a hemodynamic term, defined by pulmonary artery pressure 
above 25 mmHg at rest, irrespective of the cause and vascular resistance. Thus, both 
pulmonary arteriolar obstruction,venous obstruction and increased flow and pressure 
through large post-tricuspid shunts can produce pulmonary hypertension. Earlier 
guidelines also included mean pulmonary artery pressure above 30 mmHg during 
exercise(17). This was excluded from the 2009 version, due to its lack of discrimination 
between health and disease(18). 
Pulmonary arterial hypertension is a group of rare, usually progressive conditions, 
hemodynamically defined by a mean pulmonary artery pressure above 25 mmHg with a 
left atrial pressure/pulmonary wedge pressure below 15 mmHg. A pulmonary vascular 
resistance > 3 Wood units is also used as a criterion, but less emphasized in the presence 
of intracardiac shunts as these lesions make pulmonary vascular resistance measurements 
less reliable. In these situations, ratios of systemic to pulmonary flow and resistance 
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ratios (Qp/Qs and Rp/Rs) are often used, with Rp/Rs above 0.3-0.4 as a commonly 
applied cutoff. 
Eisenmenger’s syndrome is a clinical condition, first related to congenital heart disease 
in 1897(19). Its relation to pulmonary vascular resistance was described later by Paul 
Wood (20;21). Strictly, it is PAH due to a nonrestrictive congenital post-tricuspid shunt 
with reversed shunt flow, cyanosis and secondary erythrocytosis. Patients with surgically 
created shunts and univentricular conditions may develop similar pathophysiology. Most 
authors also include pre-tricuspid shunts, despite hemodynamic differences. Shunts 
between these low pressure chambers primarily relates to diastolic ventricular pressures.  
Eisenmenger physiology is a hemodynamic term, which, in addition to classical 
Eisenmenger’s syndrome, often includes patients with normal saturations at rest. These 
patients may desaturate during exercise only, and represent different points at a disease 
continuum between less advanced PAH-CSPS and Eisenmenger’s syndrome. 
 
 
1.2.3 WHO classification of pulmonary hypertension 
 
The first WHO classification (1974) of PH with two main categories (primary and 
secondary) was completely restructured into five categories at the second world 
conference in Evian in 1998. Further revisions were accomplished in 2003 (17) and at 
Dana Point 2008, introducing a sixth group, pulmonary venoocclusive disease/capillary 
hemangiomatosis (see table below). This classification serves as the framework for the 
updated treatment guidelines from ERS/ESC(18)  ACCF/AHA(22). Although supported 
by AEPC, the classification primarily holds an adult cardiology perspective and still has 
shortcomings with respect to the great variety of causes of pediatric pulmonary vascular 
disease. The PAH-CSPS subclassification has become more detailed (below), a problem 
being that the defect size cutoffs are not indexed for BSA. Recognizing that pediatric PH 
often is more complex in presentation and diagnosis than adult disease (23), a pure 
pediatric classification system was suggested by the Pulmonary Vascular Research 
Institute in 2011. This has ten main categories, listed according to their supposed 
importance (24). 
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WHO/ESC PH main groups (Dana Point -09)* 
 
1. Pulmonary arterial hypertension (PAH) 
  PAH related to CSPS is one of several PAH subgroups 
1’   Pulmonary venooclusive disease and pulmonary capillary hemangiomatosis 
2. PH owing to left heart disease 
3. PH owing to lung disease and/or chronic hypoxia 
4. Chronic thromboembolic PH 
5. PH from unclear multifactorial mechanisms 
 
Subclassification of PAH related to CSPS  
 
A. Eisenmenger’s syndrome 
Large defects with left to right shunt that has led to pulmonary vascular resistance 
increase. Patients have resting cyanosis, erythrocytosis and multiple organ disease. 
Cyanotic, large ASD included. 
B. PAH associated with S-P shunts. 
Moderate to large defects with mild to moderately increased pulmonary vascular 
resistance. Left to right shunt still largely present. No cyanosis at rest. ASDs included. 
C. PAH with small defects. 
VSD < 1 and ASD < 2 cm (applies for adults only) Clinical picture similar to IPAH 
D. PAH after corrective surgery 
No residual defect. PAH either present directly after surgery or recurred after years.  
* Reference (17) 
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1.2.4 Epidemiology 
 
A recent review estimated that worldwide, 3 million children are at risk of developing 
PAH related to CHD, the majority having a repairable heart defect such as ASD or 
VSD(25). Only 2-15 % of all patients with significant shunt lesions receive curative 
treatment, leaving CHD as one of the main contributors to PAH prevalence in the 
developing world (26). This means that the most effective strategy to reduce pediatric 
PAH incidence, would be to increase the availability of congenital heart defect repair for 
children in developing countries. Representing developed countries, a Dutch 
retrospective registry study found a 4.2 % prevalence of PAH and 1 % Eisenmenger’s 
syndrome among 5970 adult CHD patients. Within the subgroup with septal defects 
(n=1824), 6,1 % had PAH. An underestimation was assumed, and a 5-10 % prevalence is 
considered realistic(27;28) 
Two large registries of pediatric pulmonary hypertension have recently been established. 
TOPP is a pediatric registry that was started in 2008, with 571 patients included as of 
february 2012. 60 % of these are female. Data from the first patients shows that the 
largest subgroup was PAH (88%), whereof associated (secondary) pulmonary arterial 
hypertension was 43%, and 85% (115) of these were CHD-PAH. Trisomy 21 was 
reported in 13% of all PH patients (29). 
REVEAL is a large, multicenter, US-based PAH registry with completed enrolment. The 
3500 included patients, ages 3 months and up, will be followed for five years from 2009. 
A recent study  of risk factors, analyzed 216 patients <18 yrs , 30 % being CHD-PAH 
(30). Five-year survival was 74 +/- 6%. Surprisingly, no difference was found between 
IPAH and CHD-PAH (more unrepaired than repaired). Age at diagnosis was the only 
significant risk factor. These registries may have a survival bias, but are representative of 
clinical cohorts, and will provide unique insight into important prognostic factors, 
improving the evaluation of treatment effects. 
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Although these estimates are variable, it seems reasonable to state that, as the number of 
CHD patients that survive into adulthood may be increasing, PAH-CSPS will persist as a 
problem, even in the developed and wealthy parts of the world. This means that 
prevention, but also tools for detection, treatment decisions and monitoring of PAH-
CSPS will be of importance for an increasing number of patients.  
 
 
 
1.3  Pathophysiology of PAH development in congenital 
systemic to pulmonary shunts 
 
1.3.1 PAH-CSPS disease mechanisms in general 
 
Flow and pressure induced mechanical forces act on the pulmonary endothelium as the 
first hit. Continuously increased blood flow mediates increased shear stress. In the case of 
a post-tricuspid, nonrestrictive defect (e.g. large VSD) there is additional cyclic, pulsatile 
stress on the vascular walls. This is probably aggravated by increased pulmonary pulse 
pressure, as in a large PDA or with the coexistence of significant pulmonary 
regurgitation. The exact link between wall stress and early wall change is unclear. 
Experimentally, and supported by human data, mechano-chemical transducers in the 
endothelium can stimulate the release of smooth muscle cell growth factors. Another 
possible pathway is leak of serum factors through an overstretched endothelial cell layer, 
into the subintimal layers, triggering proteases that partly act through inflammatory 
mechanisms, starting proproliferative and antiapoptotic signaling. Distal migration of 
smooth mucle cells to normally unmuscularized arterioles, has been shown to be driven 
by gradients of matrix molecules such as fibronectin (31;32)  
The histopathological results of these processes are:  
 
- Smooth muscle cell phenotypic change, proliferation, migration, hypertrophy and        
sustained vasoconstriction 
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 - Endothelial cell phenotypic change and proliferation, neointima formation 
 - Fibrous tissue deposition  
 - Necrosis, calcification and loss of arterioles 
 - Dysfunctional neovascularization and plexiform lesions 
 
There is evidence that even in advanced disease, mechanisms differ between 
idiopathic/hereditary PAH and PAH associated with diseases such as CHD. Plexiform 
lesions look similar on a light microscopic level but contain monoclonal cells in IPAH 
and are polyclonal in associated PAH (33). Similarly, the TGF beta-1 pathway was found 
to be involved in the pulmonary vascular responses in IPAH, but not in Eisenmenger’s 
syndrome (34). 
However, three important signaling systems are brought out of homeostasis in all PAH 
subgroups. These pathways represent the three main categories of drug of the current 
treatment armamentarium: 
 
1. Endothelin pathway 
2. Prostacyclin/Thromboxane-cAMP pathway 
3. NO-cGMP pathway    
 
The status of these regulatory pathways contribute to pulmonary arteriolar vasomotor 
tonus and the degree of proliferation and apoptosis of endothelial and smooth muscle 
cells in the pulmonary vascular walls. 
 
 
1.3.2 Inflammation in pediatric heart failure related to left to right 
shunts 
 
Inflammatory mechanisms have become an established part of the understanding of  
chronic heart failure in adults, possibly contributing to symptoms such as cachexia 
(35;36).  However, the role of inflammation in heart failure due to CSPS is unclear, as 
well as its role in the very early and reversible stages of the pulmonary vascular process 
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resulting in PAH-CSPS. The only relevant study (37) demonstrated elevated cytokine 
levels in 15 infants with heart failure from left to right shunts, as compared to a group of 
cyanotic patients with Tetralogy of Fallot. This represents a potential type 1 error 
(incorrectly rejecting the null hypothesis), because comparing with a “hemodynamically 
opposite” patient group may have exaggerated the group differences.  Study III of the 
present thesis was designed to investigate the presence of inflammatory responses in the 
period of pulmonary vascular stress due to overcirculation, long time before irreversible 
vascular wall damage has become established.  
 
1.3.3 Inflammation in PAH-CSPS 
 
Inflammatory mechanisms have an established role in the pathophysiology of IPAH and 
several subclasses of adult associated PAH plus other PH groups (38-48) 
Looking at the subgroup PAH-CSPS only, the literature is more scarce, with a few papers 
indicating the significance of inflammatory mechanisms.  
Levy et al studied lung biopsies from children with PAH-CSPS (Down syndrome 
excluded), sampled at time of repair (49). Patients were considered having reversible or 
irreversible PAH-CSPS, based on invasive measurements one year postoperatively. 
Irreversible PAH-CSPS was strongly associated with impaired apoptosis, induced by 
perivascular inflammatory cells, leading to intimal proliferation. The antiapoptotic 
protein Bcl-2 was highly expressed in all cases of irreversible, but not in reversible PH. 
The reverse was seen for proapoptotic proteins p53 and caspase-3. These findings are 
supported by in vitro data (50). This suggests that early apoptosis in reversible PAH is 
followed by the inflammation driven development of apoptosis resistant endothelial cells 
and intimal proliferation, denoting irreversible disease. In further support of inflammation 
as part of PAH-CSPS development, Pinto et al analyzed 26 lung biopsies from patients 
with PAH-CSPS compared to healthy controls and found a predominance of recently 
recruited macrophages infiltrating peripheral pulmonary artery walls, related to intimal 
proliferation, together with decreased numbers of regulatory T-lymphocytes, possibly 
reflecting a deviant immune response (51).  
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Geiger et al, demonstrated increased VEGF expression in the plexiform lesions of CHD-
pulmonary arterial hypertension (52), and Grosjean has pointed out a possible role for the 
inflammatory regulator NF- kappa B in VEGF-signalling, determining endothelial cell 
survival which points to a possible inflammatory pathway in advanced disease(53).  
In sum, the presence of inflammation in PAH-CSPS is indicated in late and irreversible 
stages, but the links between inflammation and dysfunctional cell growth in PAH-CSPS 
are far from clarified. Animal models may provide important data on the early phase of 
disease development (54;55). 
 
1.4 Treatment of pulmonary hypertension related to congenital 
systemic to pulmonary shunts 
 
Treatment with the three subclasses of PAH drugs (prostanoids, endothelin receptor 
antagonists and phosphodiesterase inhibitors) in pediatric pulmonary arterial 
hypertension was almost undescribed at the initiation of study I in 2001. This included 
subgroups such as PAH-CSPS. Pediatric data had been published for prostacyclin only 
(56). Small, open label studies were published during the study period.  
 
Later developments: 
At present (but not at the time of the study I of this thesis) bosentan and sildenafil tablets 
are officially approved in Norway for PAH-CSPS, functional class II and III. The 
BREATHE 5 trial (57) with 54  patients with Eisenmenger’s syndrome, was the study 
that led to this approval. It has been followed up by an open label extension study (58), 
showing continued effects on functional status. Less specifically designed studies have 
confirmed these findings (59-61). The pivotal sildenafil study (SUPER-1), had less focus 
on CHD(62), but in a recently published pediatric PAH study sildenafil improved 
peakVO2, functional class and hemodynamics at medium and high dosage. However, 
importantly, increased mortality was seen at the high dose level in the open extension 
study (63). A recently published retrospective analysis of 229 patients with 
Eisenmenger’s syndrome concludes with a surprisingly much lower death risk 
(unadjusted HR 0.21, adjusted 0.10) for those receiving new vasodilator drugs, as 
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compared to patients receiving conservative treatment. These data should be interpreted 
with caution until they are reproduced, as it is a retrospective, single tertiary center study. 
However, results as these, rapidly get an impact in clinical decision making. The 
increasing use of the new PAH drugs, has not been followed by a development of exact 
and clinically valid monitoring and decision making tools relevant for PAH-CSPS. The 
importance of treatment monitoring is underscored by the fact that the drugs may have 
significant adverse effects, and even lead to increased mortality (64-66). 
 
1.5 Disease assessment and monitoring in PAH-CSPS 
 
PAH is a concealed disease, the site of primary pathology being the small arterioles in the 
lungs, not (yet) accessible for precise invasive or noninvasive functional assessment, nor 
for in vivo imaging techniques. Techniques for direct, in vivo assessment of the 
pulmonary vasculature are considered a major evidence gap in the latest ESC guidelines 
along with the lack of PH disease markers in general(http://www.escardio.org/guidelines-
surveys/esc-guidelines/GuidelinesDocuments/Essential-Messages-PH.pdf). Further, the 
hemodynamic consequence of arteriolar disease, total pulmonary vascular resistance 
elevation, can be difficult to measure reliably, especially in the presence of an open 
systemic to pulmonary shunt (67). Exact methods for Qp/Qs and thus, Rp/Rs 
measurement are needed. Vasodilator test protocols and cutoff values are still debated, 
and other markers of reversibility are just being explored. Hence, markers of disease 
progress constitute an important research field, in which most contributions so far comes 
from the adult PAH area. Children pose specific challenges with respect to assessment 
methods that require cooperation, such as exercise tests. Treadmill tests are reliable from 
around age 8 and 6MWT has been applied from age 4. Symptoms are often reported 
through parent interviews. A review on the challenges of assessing pediatric PAH was 
published (68) concluding that it is a specialized PAH centre task evolving from invasive 
gold standards towards non-invasive assessments.  
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1.6 Exercise induced PH in CSPS  
 
Previous versions of the WHO definition of PAH included both a resting and an exercise 
mean pulmonary artery pressure cutoff value, as alternative diagnostic criteria. The 
exercise definition (30 mmHg) was excluded from the Dana Point classification, due to 
the high exercise pressures reported in apparently healthy individuals, such as endurance 
athletes(18).  ESC publications list exercise responses as the number one gap in PH 
evidence (http://www.escardio.org/guidelines-surveys/esc-
guidelines/GuidelinesDocuments/Essential-Messages-PH.pdf). Measuring pulmonary 
artery pressure during exercise can be done invasively, but is also reliably estimated by 
echocardiography(69;70). This is performed in many centers as part of the evaluation of 
unexplained exertional dyspnea. Studying patients with systemic sclerosis with normal 
resting pressures invasively, Saggar described four categories of pulmonary vascular 
response to exercise: normal response, pure precapillary exercise PH, venous exercise PH 
and out of proportion precapillary reaction to increased pulmonary venous pressures (the 
so called Kitajev reflex)(71).  Around 150 invasive exercise studies per year are 
performed at Massachusetts General Hospital, including wedge measurements during 
exercise. Among the diagnoses are exercise induced heart failure with preserved ejection 
fraction (exercise induced diastolic dysfunction) (72) (www.phaonlineuniv.org). In 
systemic sclerosis, pure precappillary exercise induced pulmonary hypertension was 
found in 37% of cases with normal resting pulmonary artery pressure, representing 
subclinical disease. (71) Asymptomatic family members of patients with IPAH who carry 
BMPR2 mutations, show abnormal exercise response, possibly indicating the presence of 
subclinical disease. In a recent thesis from our centre, the presence of increased right 
ventricular systolic pressure during supine bicycling in patients with cardiac septal 
defects was studied, and found to be of surprisingly high prevalence(16). However, 
whether this represents subclinical increased pulmonary arteriolar resistance (reversible 
or irreversible) or exercise induced heart failure with preserved ejection fraction was not 
explored. The relation between exercise induced pulmonary hypertension and exercise 
capacity (VO2) was described in a large invasive study by Tolle (73), but this association 
was not present in the ASD/VSD population studied at our centre(74). 
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2. Aims of the studies 
 
A general aim for all studies in this thesis was to investigate potential monitoring 
parameters in patients with pulmonary arterial hypertension related to congenital heart 
defects. The specific aims of the four papers of the thesis were: 
 
2.1 Paper I 
The primary hypothesis was that a positive symptomatic effect of bosentan in patients 
with Eisenmenger’s physiology would be associated with improvement in 24-hour 
oxygen saturation measurements. Further explorative hypotheses were that change of 
peak VO2 during treadmill testing, and selected blood tests would be associated with 
changes in PAH symptoms score. 
 
2.2 Paper II 
 
This prospective follow-up study was part of the previous study. The aim was to describe 
circulating markers of inflammation and endothelial activation in patients with CHD-
PAH, as compared to healthy controls and as changes by treatment with bosentan. 
Patients with Down syndrome were analyzed separately because of their known 
susceptibility to develop pulmonary arterial hypertension. 
 
2.3 Paper III 
 
In this cross-sectional study of patients with systemic to pulmonary shunts, the aim was 
to explore the associations between the degree of pulmonary hemodynamic load and the 
levels of circulating markers of inflammation and endothelial activation. Again, the 
significance of Down syndrome diagnosis was studied separately.  
.  
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2.4 Paper IV 
 
This RCT examined exercise induced pulmonary hypertension in patients with cardiac 
septal defects. The primary hypothesis was that pulmonary vasoconstriction was present 
and would be responsive to sildenafil, accompanied by increased peak VO2. 
At an explorative level, left ventricular diastolic reserve and its association with right 
ventricular systolic pressure during exercise was studied. Effects of sildenafil on 
indicators of right and left ventricular systolic function were also described. Lastly 
(unpublished data) alveolocapillary membrane area size was estimated by diffusion 
capacity for carbon monoxide during exercise with and without sildenafil.  
 
3. Methodological considerations 
 
3.1 General considerations 
 
OUS (Rikshospitalet) was the only surgical CHD centre in Norway during this study 
period. Thus, the consecutively recruited patients in paper III can be regarded as a 
population based sample. All studies were performed in accordance with the Helsinki 
declaration of 1964 including later amendments (www.wma.net). Written informed 
consent was acquired. Children above 12 years read and signed a specially written assent 
form in addition to the one read and signed by the parents. All studies were accepted by 
the regional ethics committee and study IV was registered at www.clinicaltrials.gov as 
appropriate for drug studies. At the initiation of study I, this was not generally required, 
and the registration service was not established.  
 
3.2 Recruitment and selection of patients and controls 
 
3.2.1   Patient group, paper I 
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Patients with classical Eisenmenger’s syndrome, L-R shunt at rest but desaturating during 
exercise and some with “greyzone” pulmonary vascular resistance index were included. 
Thus, the use of the term Eisenmenger’s syndrome in the title is a simplification from a 
period of less precise term definition. According to today’s nomenclature, Eisenmenger’s 
physiology may be preferable. However, these patients were all in development of PAH 
that would end with Eisenmenger’s syndrome. A list of patients waiting for trials of new 
pulmonary vasodilator drugs had been accumulated and kept for some time in the 
department, and these patients/families were contacted. All families accepted 
participation. New patients that were admitted for evaluation during the study period 
were also asked for participation.  
 
3.2.2 Systemic to pulmonary shunt group (paper III) 
 
Oslo University Hospital is a tertiary level hospital which at the time of the study had 
achieved nationwide responsibility for neonatal pediatric cardiac surgery and also 
performed the great majority of catheter interventions in CHD. Patients admitted for 
definitive treatment of ASD or PDA (n=55) were enrolled during the years 2002-4. 
Patients with VSD and AVSD (n= 19) were recruited during the second half of the study 
period, following an amendment based on a desire to include a wider spectrum of 
pulmonary vascular hemodynamic load. The parents of patients scheduled for 
interventional catheterizations were prospectively asked for participation. Demographic 
or other characteristics of the limited number of patients who declined participation were 
not registered. Exclusion criteria were those that would preclude the child to anesthesia, 
i.e. active infectious disease, as evaluated by clinical examination, chest radiogram and 
CRP level. 
 
 
3.2.3 Exercise PH group (paper IV) 
 
Patients with known exe-PH and VSD from the previously mentioned study from our 
centre were asked, and nine accepted participation. Further ten patients from south 
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eastern Norway previously operated for VSD, were screened for exercise induced 
pulmonary hypertension  by reclined bicycle echocardiography, resulting in six more 
patients filling inclusion criteria, of whom five accepted participation.  
 
3.2.4 Control group – CSPS and PAH-CSPS study (paper II and III) 
 
As healthy controls, we included otherwise healthy children admitted to the skin 
department for laser treatment of capillary hemangiomas, some children of hospital staff. 
All were screened clinically and by CRP levels for intercurrent infectious disease.  
 
3.3    Clinical examination and symptoms scores 
    
Clinical assessment 
 
A standard pediatric history taking and clinical examination was performed in all 
patients, including heart and lung auscultation, measurement of the extension of the liver 
below the costal margin, palpation of peripheral pulses, standardized supine resting blood 
pressure measurement, assessment of respiratory rate and peripheral microcirculation.  
Systolic blood pressure was measured as the average of two measurements at the time of 
echocardiography, by standard automated sphygmomanometry (Dinamap, GE 
Healthcare, WI, USA) 
 
Symptoms scores 
 
In effort to standardize description of symptoms and their change, specific PAH and 
pediatric heart failure symptom scores were sought in the literature. The Ross score of 
infant heart failure and the pediatric PAH score used by Bowyer et al were the ones 
identified as applicable at the time (75;76).  
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Heart failure symptoms score 
 
The scoring system for pediatric heart failure published by Ross (75), was applied in 
study III. To extend its applicability into higher age groups, we replaced the item 
“feeding” with reported activity level for patients above 12 months of age. 
 
 
Ross score table  (modified)  
Score 0 1 2 
Respiration Normal Abnormal/exertional  
dyspnea 
--- 
Respiratory 
pattern 
Normal Abnormal --- 
Peripheral 
perfusion 
Normal  Decreased --- 
HR/min <160/normal 160-170 >170 
Feeding volumes  
Feeding time 
>100ml 
< 40 min 
 
70-100 
> 40 min 
<70ml 
--- 
Activity level 
(replacing 
feeding time after 
12 months age) 
Normal Moderately 
decreased 
Severely 
decreased 
Liver edge <2cm 2-3 cm >3 cm 
S3/diastolic 
rumble 
Absent  Present   
Total score:  0-2: no heart failure, 3-6: mild heart failure, 7-9: mod heart failure,  
10-12: severe heart failure(74). 
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WHO/NYHA class was assigned to all PAH patients in study I, at all checkups, based on 
the history. Further, a pediatric PAH symptoms score, interviewing patients and 
caregivers about five specific areas of functional status was applied (76).A high score 
denotes good functional status.  
 
 
PAH symptoms score* 
 0 1 2 3 4 
School 
participation 
none <50% 50-100% or 
special 
school 
Full 
school, 
Sport 
limited 
Full 
school, 
Full sport 
Walking flat Breathless at 
rest 
Breathless 
on minimal 
exertion 
30-50 m 
slow, OK 
100-400 m 
slow, OK 
3 km 
slowly, 
OK 
Running/jogging Never Few paces 
only 
20 m gently, 
OK 
100 m 
jogging, 
OK 
Normal 
speed 
100 m 
Walking stairs Never tries 1 flight 
difficult 
1 flight OK, 
2 is difficult 
2 flights 
OK at 
average 
speed 
normal 
Tiredness always Very 
quickly 
tired each 
day after 
school 
Frequently 
tired 
Sometimes 
after long 
day 
normal 
* Reference (75). 
 
 
3.4 Radiography  (paper III) 
 
Standard front and lateral views were reviewed for pulmonary vascular markings and 
heart size by an expert pediatric radiologist, unaware of the clinical data. Both issues 
were assigned a score of 0-3 points, denoting no, mild, moderately and severely 
increased, respectively. This was combined with echocardiographic measurements to 
categorize patients into the low or high pulmonary blood flow groups (see next section 
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for details).The assessment of chest radiograms was performed subjectively, as per 
clinical practice. In the PAH study (study I), chest radiograms were not used as follow-up 
parameter.  
 
 
3.5 Echocardiography  
 
All  the patients in paper I-IV had a standard clinical pediatric echocardiogram performed 
to confirm the diagnosis, and to rule out additional cardiac pathology that would lead to 
exclusion, such as right ventricular outflow tract obstruction, pulmonary artery branch 
stenosis or impaired ventricular function.  
 
3.5.1 Echocardiography in the CSPS study (paper III) 
 
The measurement methods in paper III are all part of standard clinical echocardiographic 
evaluation of congenital heart disease, as recommended in past and current clinical 
guidelines. 
 
Pulmonary artery pressure 
In patients that were not catheterized, pulmonary artery pressure estimation and 
categorization were based on echocardiographic estimates using the modified Bernoulli 
equation. Right ventricular outflow tract obstruction was ruled out by echocardiography 
in all patients. Shunt flow velocity and tricuspid valvar regurgitant flow velocity tracings 
were registered from all standard views in order to obtain the optimal continuous wave 
Doppler beam direction and maximal velocity. Based on the VSD or PDA peak systolic 
flow velocity or tricuspid regurgitant flow peak velocity, patients were allocated either to 
the high (pulmonary artery systolic pressure above 50 % of systolic systemic blood 
pressure) or low (PASP below 50 % of SBP) pressure group.  
 
Pulmonary artery flow 
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In all patients, left ventricular end diastolic diameter Z-score by parasternal short axis m-
mode, left atrium/Aortic root ratio by parasternal long-axis m-mode and indexed atrial 
areas from the apical four chamber view were registered, in order to quantify the degree 
of excessive volume load. All echocardiographic measurements were done offline, using 
the Echopac software (GE, Horten Norway), en bloc and performed in duplicate or as the 
average of three if the first two differed more than 10 %. In the case of a VSD or PDA, 
the left atrium and left ventricle indexed dimensions were used, and in an ASD, indexed 
right atrial area was used for evaluation of volume load, comparing the right and left 
atrial area tracings. These measurements were done blinded to the other clinical and 
hemodynamic data and to the inflammatory marker levels. Based on these measurements, 
patients were decided to have mild, moderate or severely increased pulmonary blood 
flow. Held together with the radiographic findings, patients were then allocated to high or 
low flow group as follows. Patients with mild or inconsistent (mild/moderate) echo and 
radiographic findings indicative of pulmonary hyperflow, were allocated to the Qp/Qs < 
2,5 group. Those with consistently moderate to severe echocardiographic dilatation or 
heart size/vascular markings were allocated to the QpQs> 2,5 group. Estimated Qp/Qs by 
pulsed wave Doppler tracing areas and aortic/pulmonary valve annulus diameter demands 
a high image quality and were only used for classification of a few patients with good 
quality tracings and consistent findings.   
As an indicator of coherence between methods, the combined echocardiography and 
chest radiogram based Qp/Qs categorization method was compared to the invasive 
measurements in patients who had been evaluated by both methods. Significant 
Spearman’s correlations were found between all individual noninvasive indicators and 
the Qp/Qs estimated by the Fick method.  
 
 
3.5.2 Echocardiography in the PAH-CSPS (bosentan) study (paper I) 
 
At all check-ups, standard clinical echocardiograms were recorded, evaluating 
qualitatively biventricular systolic function and valvar function for safety purposes. Shunt 
flow velocity, eccentricity index and tricuspid and pulmonary valve regurgitation 
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velocities were measured as applicable for the cardiac defect. Pulsed wave measurements 
of shunt flow velocity and direction (77) were recorded as a possible outcome indicator 
of change in the Rp/Rs ratio.  No consistent change of echocardiographic measurements 
could be registered and these data were not statistically analyzed or reported.  
 
3.5.3 Exercise echocardiography (paper IV) 
 
Exercise echocardiography, both for right ventricular systolic pressure estimates and 
tissue Doppler based ventricular function, are research methods, with an undefined 
position as clinical tools. We used stress echocardiography to: 
1. Assess changes by sildenafil in pulmonary vascular resistance during exercise 
indirectly, by measuring right ventricular pressure. Doppler measurement of 
pulmonary blood flow during exercise was evaluated as too inaccurate. 
2. Describe changes in systolic and diastolic function of the left and right ventricle 
with increasing exercise level. 
The stress echocardiography method, measuring i.v. saline enhanced TR jet peak 
velocities by CW Doppler during reclined bicycling has been validated against invasive 
measurements(69). It has been described with respect to its feasibility without saline 
enhancement (78), and the intra- and interobserver reproducibility of the method as 
applied in the present protocol was documented in a previous study performed at our 
centre(79), providing a detailed description. Echocardiographic images during exercise 
were registered by one experienced cardiologist (T.M.) with patients cycling constantly at 
60 rev/min. Digitally stored images of TR jet velocities were analyzed offline, en bloc by 
one observer, registering the average of peak values from two good quality tracings for 
each stage, accepting only studies with evaluable tracings from at least the second last 
exercise stage (all studies accepted). The study of left ventricular diastolic function 
during exercise by tissue Doppler echocardiography has been described (80). This 
method has obvious limitations of reliability as a clinical decision making tool, but these 
are of less importance as we used the patient as her own control in an acute study. Mitral 
flow velocities for the calculation of E/E’ ratios were not recorded in this study. Again, 
paired comparisons makes this less important. Apical four chamber TDI images 
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(minimum three cardiac cycles) were recorded at all stages. All tissue Doppler images 
were analyzed offline, en bloc by one observer (HB), using the Echopac software (GE, 
Horten Norway). Manual, frame by frame myocardial tracking was applied as necessary 
to reduce curve disruption from respiratory movements. Peak systolic velocity was 
defined as the highest positive velocity measured after the onset of QRS and before the 
aortic valve closure time point, indicated by the software. Peak diastolic velocity (during 
exercise) was, in the absence of clearly defined separate A’ and E’ waves, defined as the 
highest negative velocity between aortic valve closure and onset of QRS. With a right 
ventricular flow outflow tract Vmax above 2m/s at 100 W as exclusion criterion, no 
patients were excluded due to dynamic obstruction. Further details are provided in the 
methods section of paper IV. 
 
 
3.6 Cardiac catheterization and blood sampling protocol 
 
In adult patients and the absence of a S-P shunt, right heart catheterization with 
thermodilution based cardiac output measurement and pulmonary vascular resistance 
estimation is regarded as the gold standard for describing changes in the pulmonary 
vasculature. This, already, implies simplifications, such as the application of Ohms law 
when calculating pulmonary vascular resistance. In children with cardiac shunts, invasive 
data are less precise, because intubated anesthesia is required. Unavoidable changes in 
pCO2, oxygenation, stressors, sedation and anesthetics during the procedure change 
hemodynamics, and may create big errors in the Qp/Qs and Rp/Rs data. Missing 
measurements of pulmonary venous saturation may lead to pulmonary flow 
overestimation. Further, catheterization in general anesthesia has been considered a high 
risk, especially in highly symptomatic PAH patients which makes it less useful as regular 
follow-up tool. Thus, no patients in the present studies were catheterized for scientific 
purposes alone.  
A standard clinical catheterization protocol was followed for the evaluation and treatment 
of patients with ASD and PDA in study III. In study I, catheter data were collected 
retrospectively from clinically indicated catheterizations. All studies were performed with 
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the patient in general anesthesia, breathing room air, in a situation as hemodynamically 
stabile as possible in this setting. In patients with ASD, both pulmonary artery pressures 
and pulmonary to systemic flow and resistance ratios were calculated, based on the Fick 
principle. Oxygen consumption was not measured, and the vascular resistances thus were 
expressed as a pulmonary to systemic ratio. Due to incomplete mixing of blood at the 
sampling site in patients with PDA, oximetry based shunt flow estimate is unreliable. 
Thus, only pulmonary artery pressures were reported from the invasive data in patients 
with PDA. In patients with elevated pulmonary artery pressure, left atrial or pulmonary 
wedge pressure was measured. The values for wedge pressure measurements were within 
normal values in the catheterized patients (not reported in papers). Vasoreactivity testing 
was not part of the scientific protocol.  
Blood samples were drawn from the inferior caval vein, away from the renal veins, and 
from the left atrium or femoral artery. Plasma level values from the central venous blood 
samples were subtracted from the arterial sample values to calculate transpulmonary 
gradients. This was studied as a measurement of net release or uptake of the analyzed 
inflammatory markers in the pulmonary vascular bed.  
Catheterized patients had blood samples drawn from the antecubital vein on the day 
before the procedure to compare with the venous samples drawn during anesthesia in 
effort to control for any effects on the inflammatory markers induced by anesthesia. 
 
 
3.7 Cardiopulmonary exercise testing 
 
 
In PAH assessment, exercise testing holds a central position, as loss of exercise tolerance 
is one of the main symptoms of the disease. Cardiopulmonary exercise testing as a 
maximal exercise test (treadmill or bicycle) with breath to breath gas analysis, has been 
extensively used in assessment of adult PAH and can usually be performed in children 
from the age seven (81) (82). Traditionally, however, the six minute walk test has been 
used in most adult PAH treatment studies, although being a submaximal exercise test, 
correlating with hemodynamics and outcome (83). With a 6MW result above 300 m, a 
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cardiopulmonary exercise test has been recommended for a more detailed description of 
exercise ability, and most of the participants in study I were NYHA class II. At the time 
of inclusion in study I, there was little data published on the use of 6MW in children, and 
large variation due to motivational factors was assumed. Cardiopulmonary exercise test is 
reliable and suitable for serial measurements during follow up(81). Peak VO2 in children 
with PAH has been shown to correlate with pulmonary vascular resistance index (r = -
0,6, p= 0,006)(84). Thus, for the assessment of exercise ability in study I, 
cardiopulmonary exercise test on treadmill was chosen, due to the experience in the 
group (85), although this resulted in some participants not being able to perform these 
studies. Some of these, in retrospect, could have performed 6MW tests, However, the 
PAH symptom score (above) covers similar information on functional capacity by 
interview.  In study IV, cardiopulmonary exercise test was performed as standard 
treadmill testing at inclusion. Further, VO2 was measured during the reclined bicycling 
studies for intra-patient comparison. All treadmill exercise tests in paper II and IV were 
performed by the same experienced physiotherapist (PMF), accompanied by a 
cardiologist (HB).  
 
3.8 Twenty-four hour oxygen saturation measurement (paper I) 
 
The principal idea of study no I was to explore and improve non-invasive parameters, 
avoiding the use of unreliable and hazardous invasive hemodynamic assessments. 
Arterial blood gas is the gold standard for oxygen saturation, but is painful and thus not 
feasible for the follow up of children. Transcutaneous oxygen saturation is widely used in 
hypoxemic patients. Acknowledging the large spontaneous variation in oxygen saturation 
values, in individual patients, over short periods of time, we chose a long measuring 
interval as way of enhancing the data representativity for the of the patients’ situation. AS 
hypoxemia is a key finding in Eisenmenger’s syndrome, the need for valid SpO2 
measurements is undebatable. However, its value as treatment monitoring parameter had 
received little attention. Clinical assessments normally include measurements for a 
couple of minutes, after a few minutes rest on a chair/bench. It has been shown that 
oxygen saturation in patients with Eisenmenger’s syndrome varies with body position, 
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probably due to ventilation perfusion distribution phenomena and/or diffusion 
abnormalities(86). We therefore assumed that longer periods of measurement would 
improve the validity of the SpO2 values. Thus, we registered during rest and activity, day 
and night, as an analogy to 24 hour ambulatory BP measurements in systemic 
hypertension. The mean value of 24 hour oxygen saturation correlated well with 
hematocrit and hemoglobin values at baseline as shown in the figures below, indicating 
that these long term measurements provide a valid indicator of the patients’ tissue 
oxygenation over time (see figures below). 
The pulse oximetry data in study I were collected in a standardized setting, during a 24 
hour hospital admission, thus minimizing variation in activity type and duration between 
the time points. All alarm functions were turned off during measurement and no patient 
received extra oxygen. Oxygen saturation and heart rate was measured transcutaneously, 
with a sampling frequency of one dataset every two seconds. Self-adhesive sensors for 
one time use were applied. Sensors were placed at the less used left or right handed index 
finger, unless the lesion involved a PDA, making foot measurement necessary. The data 
sets were cleaned for periods of low signal quality (automated software function, 
followed by manual surveillance, excluding periods with obviously deviant HR and/or 
SpO2 curves), and analyzed with the Download 2001 software (Stowood inc, UK).  
 
 
 
 36 
R2 = 0,7363
70
80
90
100
30 40 50 60
Serie1
Lineær (Serie1)
 
Figure Hematocrit (%) vs mean of 24 hour oxygen saturation (%) at baseline. 
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Figure Hemoglobin (g/L) vs mean of 24 hour oxygen saturation at baseline 
 
 
3.9  Pulmonary function tests 
 
In study I and IV, participants were examined by standard spirometry (ATS guidelines Eu 
Resp J 2005, Miller MR) at all time points. Spirometry at baseline was performed to 
exclude overt lung pathology (restrictive or subclinical obstructive disease) that could be 
relevant for the development of  PAH. As no significant changes or deviations from 
normal were seen in the spirometry data, these were not considered of importance for the 
conclusions in the papers or thesis. Coherently, no association between FVC and 
abnormal right ventricular pressure response during exercise was found in our previous 
ASD and VSD study (87). In study IV, DLco measurements were performed at rest and 
during exercise, as DLco has been used as a surrogate marker for available pulmonary 
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capillary bed area, expecting that if sildenafil lowered pulmonary vascular resistance, 
DLco would increase.  
 
3.10 Biochemical analyses – circulating biomarkers 
  
 
A simple blood test that tells the doctor and patient about the disease status and whether 
to intensify treatment does not exist for PAH-CSPS.  
NTproBNP values may be difficult to interpret in the presence of S-P shunts, as the shunt 
flow initially imposes neurohumoral activation and cardiac peptide elevation due to 
volume overload of the right and or left ventricles. With time, as pulmonary vascular 
resistance increases, NTproBNP will decrease with the reduction of the shunt flow, until 
a new increase occurs as result of pressure load and gradually developing right 
ventricular failure. Thus a normal peptide value in this condition can be present with high 
pulmonary vascular resistance but good right ventricle function.  
At the initiation of study I, cardiac peptides were emerging as markers of heart failure, 
also in pediatric literature (88). However NTproBNP replaced ANP as routine analysis at 
our centre during the study, implying that complete datasets are not available for all 
patients in study I. In study III, however, The NTproBNP analyses were performed 
systematically and outside clinical routine, ensuring completeness and maximal 
reiliability of data. NT proBNP was also not described as an assessment parameter in 
pediatric PAH at the time of start study I, but proANP (later NTproBNP) was measured 
as part of the safety protocol, in the case treatment with bosentan should be so effective 
that volume overload resumed.  
Uric Acid had a demonstrated prognostic value in IPAH(89), and was thus included as a 
possible marker of symptomatic improvement in the present PAH patients.  
Hemoglobin and hematocrit have specific roles in monitoring Eisenmenger’s patients, 
together with iron status, as very high Hct levels, above the 0.70 range, lead to a 
dramatical increase of total pulmonary vascular resistance, often accompanied by iron 
deficiency with further increased viscosity by poorly deformable microcytes. Further, a 
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decline in Hgb/Hct was expected in the case SpO2 values should increase by bosentan 
treatment. 
Inflammation marker analysis 
Although inflammation, as represented by various established circulating markers, had 
gained a position in the pathophysiology of PAH in general, circulating markers such as 
CRP, had not and still have not become established as biomarkers. For the presented 
studies, we chose a range of established markers studied in both pulmonary and systemic 
arterial diseases and in adult heart failure, in effort to find a marker that either correlated 
well with A. signs and symptoms of heart failure (study III)  or B. PAH symptoms or 
change in symptoms with drug treatment (study II) .  
 
Biomarker assays 
Enzyme immunoassays from R&D systems (Minneapolis, MN, USA), Bender 
Medsystems GmbH (Vienna, Austria), Peprotech (London, UK) and DakoCytomation 
(Glostrup, Denmark) were used for the inflammatory markers and von Willebrand factor 
in papers II and III. All assays were carried out in the laborarory at the Research Institute 
for Internal Medicine, under the supervision of Thor Ueland.  
ELISA method: For the EIAs, standard 96 well polystyrene microtiter plates were coated 
with primary antibodies, immobilising the desired antigen to the surface, applying second 
(detecting) antibodies with enzyme, then adding substrate creating the color reaction. 
Automated detergent washing and color density reading was used. Analyses were 
performed in duplicate and blinded to the clinical data. Inter- and intra- coefficients of 
variation was <10% for all EIAs. To minimize run-to-run variability, serial samples from 
one individual were analyzed on the same plate.  
NTproBNP (paper III) was analyzed at the OUS clinical laboratory. All samples were run 
en bloc, with the instrument Modular E and commercial sandwich based 
chemiluminescence kits from Roche Diagnostics (Mannheim, Germany). Uric acid and 
Hemoglobin (paper I) were measured as routine analyses at the accredited OUS clinical 
laboratory. 
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3.11 Bosentan treatment protocol (paper I) 
After the baseline evaluation, patients were started at oral bosentan 1 mg/kg BID, 
increasing to the target dose of 2 mg/kg BID after two weeks, continuing treatment for 12 
months with monthly liver enzyme measurements and study visits every 3 months. 
Pediatric dosage recommendations were published later during the study period 
confirming the adequacy of the chosen regimen(90). 
 
3.12 Sildenafil test protocol (paper IV) 
All participants received capsules with either sildenafil 50 mg or placebo on two 
consecutive study days. Capsules were administered with a glass of water, 90 minutes 
before the study start, in a randomized, doubly blinded fashion, with at least 24 hours 
washout between the two testing time points. The applied dose is large as compared to 
the standard 20 mg dose applied in PAH treatment. A single oral dose of 50 mg has been 
effectively used in acute studies of hemodynamic effects in adults (91). 
 
3.13 Statistical methods (SPSS versions 15.0-18.0) 
 
Paper I: 0-12 month comparisons were analyzed by single sample t-test. 
Relationship between symptoms change and SpO2 change was analyzed with linear 
regression.  
 
Paper II: Skewedness of data was present, and Mann-Whitney U test was used for 
comparison of patients and controls. Treatment effects were analyzed by Wilcoxon 
matched pairs test and correlations were analyzed by Spearman’s rank test. 
 
Paper III: Group comparisons: Mann-Whitney U test. 
Compartment differences: paired t-test 
Univariate analysis: Spearman rank test 
The main analysis was done with multiple linear regression, log transforming explanatory 
and dependent variables as necessary for model fit.  
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Paper IV: Mixed models analysis for repeated measurements with random intercept and 
slope was performed by medical statistician (AHP). Normal distribution of data was 
examined by residual plots and histograms. Linear or square curvilinear relation of 
hemodynamic parameters with time and exercise intensity were applied as needed for the 
best model fit.  
4. Summary of results 
 
4.1 Paper I 
 
Among 14 patients with PAH-CSPS treated with bosentan for 12 months, all patients 
reported improvement or stability of symptoms, apart from one patient with side effects 
that required cessation of treatment. Mean of 24 hour oxygen saturation showed a small 
decline, in parallel with a lowered diastolic blood pressure. Peak VO2 (n=6) declined 
with mean 8 ml with a trend towards decreased ventilatory efficiency. Large, individual 
day to day variations of mean 30 minute supine SpO2 was demonstrated. 
 
 
4.2 Paper II 
 
Patients with PAH-CSPS were characterized by increased plasma levels of von 
Willebrand factor (endothelial cell activation) CRP (systemic inflammation), CD40 
ligand (platelet mediated inflammation) and osteoprotegerin (vascular inflammation, 
possibly involving calcium metabolism). Within the study group, NT-proBNP levels 
correlated with vWf and CRP levels. 12 months treatment with bosentan reduced MCP-1 
levels in those with improvement of symptoms and RANKL in the group as a whole. 
Patients with Down syndrome (average age 118 months) had higher s TNFR1 and MCP-
1 levels than non-DS patients and controls.  
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4.3 Paper III 
 
In 74 patients with CSPS association between hemodynamic stress  and systemic 
inflammatory markers could be demonstrated. Furthermore, no net production or uptake 
of inflammatory markers trough the pulmonary vasculature was found. As in the previous 
paper, Down syndrome was an independent risk factor for increased inflammatory 
activity. Children with CHD and Down syndrome have a different inflammatory profile 
when comparing with age matched CHD patients, irrespective of their hemodynamic 
characteristics. 
 
4.4 Paper IV 
 
In 14 patients with cardiac septal defects and known exercise induced pulmonary 
hypertension, we found no effect of sildenafil on right ventricular pressures or peak VO2 
during reclined bicycling. However, exercise induced right ventricular systolic pressure 
increase was associated with left ventricle diastolic reserve as measured by change in left 
ventricular lateral wall E’ velocity. Lastly, right ventricular systolic function improved 
with sildenafil, according to the tissue Doppler velocities and TAPSE measurements. 
 
5. Discussion PAH-CSPS - mechanisms and monitoring 
 
PAH-CSPS including Eisenmenger’s syndrome have been regarded as clinically and 
hemodynamic stable conditions even at long-term, when comparing to the rapidly 
progressive IPAH. This view is currently being challenged in adult cardiology, by studies 
demonstrating functional deterioration over short periods of time (92), and from survival 
data indicating a standardized mortality rate of 3.8 (2-7), and concluding that PAH-CSPS 
is not a stabile disease (10). An ideal disease monitoring parameter should describe 
whether the disease process is stabile, improving due to treatment or in progression. It 
should predict mortality and be reliable, simple to perform and safe. Monitoring options 
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in PAH-CSPS is far from perfect, and no significant new concepts have been 
implemented into clinical practice since the start of study I.  Therefore, the current 
clinical monitoring concept, as in all PAH treatment, is to make a qualified but subjective 
evaluation of all available parameters together(18). 
 
Currently applied outcome parameters in trials of new drugs in PAH-CSPS and 
Eisenmenger’s syndrome are: 
- NYHA functional class assessment and other clinical scores  
- Six minute walk test or cardiopulmonary exercise test 
- Circulating biomarkers, such as NTproBNP 
- SpO2  (in patients with open shunts) 
- If invasive study: pulmonary artery pressures and resistance 
 
In the following, monitoring tools are discussed, with an emphasis on those studied in 
this thesis.  
 
5.1 Functional status assessment and scoring systems 
 
The NYHA PH functional class assessment was developed for adult patients, and has 
obvious limitations for use in infants and pre-school children. With a median age of 10 
years in paper I, we applied a combination of adult-like functional class assessment and a 
symptom score that had been used in a previous PAH-CSPS study(76). The majority of 
patients were in class II, thus NYHA functional status was not considered a sensitive 
monitoring tool for this group. The pediatric PAH symptoms score, however, did 
improve with treatment. In an uncontrolled study, obviously, placebo effects and the 
parents’ expectations may account for some of this, but effects were consistent over 12 
months. However, no correlation was found between the biomarkers and the symptoms 
score. Similarly, in adult PAH studies, lack of consistency between clinical improvement 
and e.g. hemodynamic parameters are not infrequent. Holding the patient and caregivers 
experience of improved clinical condition as the treatment effect reference of this study, 
this indicates that the chosen biomarkers may not be sufficient alone in the monitoring of 
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this treatment effect. A correlation with six minute walk distance could perhaps have 
been demonstrated, but was not examined, due to the poor standardization of this test for 
children at the time. This discussion is continued below. Functional status assessment 
(NYHA classification) in pediatric PAH was recently reviewed by Lammers et al (93). 
An age-specific classification system was proposed, creating possibilities for more valid 
and reliable outcome parameters in future treatment studies. More recent pediatric PAH 
studies include quality of life and global functioning assessments (63). These may 
provide important additional information about a chronic disabling disease which has no 
available cure.  
 
 
5.2 Exercise testing in PAH-CSPS 
 
Tests of exercise capacity play a critical role in the evaluation of PAH patients. The main 
symptom of the disease is limitation of exercise ability and changes provide immediate 
information about worsening or symptom relief. Exercise assessments can be divided into 
submaximal tests, such as the 6MW and maximal tests, as treadmill or bicycle 
cardiopulmonary exercise test with peak VO2 measurement. The Borg scale is frequently 
used to assess the patients’ experience of exhaustion. The prognostic value of peak VO2, 
6MWT and response to treatment in 6MWT distance is documented in adult PAH 
(83;94). In pediatric care, the choice of test method depends both on motor skills and 
functional class. Highly symptomatic children are validly evaluated by submaximal tests, 
whereas early treatment studies should apply cardiopulmonary exercise testing (82). With 
mainly NYHA II patients in study I, we chose cardiopulmonary exercise testing, although 
this was found to be unfeasible in some patients. However, effects of treatment may be 
difficult to measure by cardiopulmonary exercise testing with peak VO2 measurement, 
perhaps because the new pulmonary vasodilator drugs tend to improve submaximal 
exercise capacity more than peak capacity (63). Submaximal exercise testing in children 
has been extensively studied in recent years. The feasibility and normal values for the 6 
minute walk test in European children from 4-11 was described by Lammers et al (95). 
This study included SpO2 data, in which 96-99 % was found to be the normal area. SpO2 
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measurement during 6MWT is recommended in PAH-CSPS with open shunts. Geiger 
studied ages 3-18 and found normal median values plateauing in girls at 11 years in the 
660 meter range(96). The male values increased further with age to 730 meters. 
Normative values may be population specific (97). Chinese normative pediatric values 
were published by Li (98). Importantly, an improvement significance cutoff of 68 m was 
found in a pediatric validation study, while 54 m has been accepted in the adult 
literature(99). Mean 6MWT improvement in drug studies is often in the 10-15 % range, 
indicating that in clinical practice, many patients will have treatment effects that cannot 
be assessed by 6MWT alone. Being a submaximal test 6MWT would probably have had 
a low discriminative value in our NYHA 2 patients.  
Pulmonary vascular resistance and right ventricular function are among factors with 
impact on exercise capacity. Pulmonary vascular resistance is a flow dependent variable. 
Flow, or cardiac output, is difficult to assess directly in this patient group. Vasodilator 
PAH drugs have other hemodynamic properties than the assumed selective pulmonary 
vascular resistance reduction. This may include inotropic effects that could enhance right 
ventricular function(100). Signs of increased systolic ventricular function were seen in 
the sildenafil study (paper IV). In study I, an endothelin receptor antagonist was used. 
Endothelin-1 has complex effects on the myocardium that may differ with hemodynamic 
situation. One could speculate that positive inotropic effects could have contributed to an 
improvement of cardiac output and exercise capacity at submaximal levels, without 
improving the maximal cardiac output and peak VO2.  
In conclusion, both submaximal and maximal exercise tests hold key positions in PAH 
assessment, the choice of method depending on NYHA class.  
 
5.3 Pulse oximetry for the assessment of patients with 
Eisenmenger physiology 
 
A principal idea of study no I was that pulse oximetry might provide enough information 
about response to therapy, thereby avoiding the use of invasive hemodynamic 
assessment. The gold standard for oxygen saturation measurement is arterial blood gas 
analysis. Finger-tip oximetry values in a later study of patients with Eisenmenger’s were 
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found to be  mean five per cent higher than arterial blood gas values (101).There are no 
published guidelines for the measurement of SpO2 in patients with Eisenmenger or PAH-
CSPS. However, there is an increasing awareness of the need for standardization of 
measurements, which may include elements such as hydration status, resting time prior to 
measurement, body position and duration of measurement. As demonstrated in figure 3, 
paper I, large day to day variations of SpO2 in patients with Eisenmenger’s syndrome are 
seen, even with standardized supine measurement for 30 minutes. As demonstrated in the 
figure below, oxygen saturation also changed significantly within the 30 minute periods 
from start to end, possibly reflecting the altered ventilation perfusion matching when 
lying down. Increased venous return from the legs in the supine position, leading to larger 
volumes of  right to left shunting could be responsible for this desaturation, but the 
saturation dip seen in this specific patient appears after approximately 10 minutes, which 
seems late, if this were the mechanism.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure: Heart rate and SpO2 measurement in Eisenmenger patient during the first 
40 minutes after lying down 
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Not all patients in study I were hypoxemic at rest. In accordance with the later Dana 
Point classification, only 8 of the 14 patients in the study had the classical Eisenmenger’s 
syndrome. The rest would currently be classified as PAH-CSPS, subgroup B, 
desaturating with exercise. Correspondingly, three patients had hematocrit values in the 
normal range, and their exercise desaturations were too infrequent or mild to be detected 
by the 5th percentile SpO2 value derived from the 24 hour SpO2 analysis at baseline 
(Table 1, paper I). In these patients, desaturations were, with our methods, observed as  
1-2 % of the measurement time period with saturations below 94%.  
The simple hemodynamic concept of study I was that, in patients with an open shunt and 
some degree of desaturation, a drug induced, selective or relative reduction of pulmonary 
vascular resistance would be detectable, either as increased mean, or maximal, 
transcutaneous oxygen saturation. In Eisenmenger’s physiology, decreased oxygen 
saturation is seen during muscle activity (due to lowered SVR) that is not accompanied 
by lowered pulmonary vascular resistance. It would be expected that in a hypoxemic 
Eisenmenger’s patient, selective pulmonary vasodilation would lead to a higher oxygen 
saturation both at rest and during activity, and thus SpO2 would be the ideal pulmonary 
vascular resistance marker. In patients with activity related desaturation only, less 
pronounced desaturations were predicted as the desirable treatment effect. However, 
other factors affect the measured SpO2, such as the systemic venous oxygen saturation 
depending on cardiac output and peripheral oxygen extraction. Thus, in right to left 
shunts, less systemic arterial desaturation follows improved cardiac output, irrespective 
of the change in pulmonary vascular resistance. With reference to Sandovals study of the 
impact of body position (86), we separately assessed 6 hours of sleep, representing the 
supine position. However, in some patients, vasodilators produce nasal congestion, 
affecting sleep breathing pattern. Patient no 2 demonstrated this kind of decreased night 
time oxygen saturation. Reduced SpO2 during sleep could also be an indicator of 
ventilation perfusion mismatch by nonselective, drug induced vasodilation that may be 
more significant in the supine position. Specific night time desaturations, however, were 
not a systematic finding in the patient group of study I. This indicates that mechanisms 
for the desaturation seen after bosentan treatment were independent of sleep induced 
respiratory disturbances. A possible explanation for the discrepancy between SpO2 
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decrease and improvement of symptoms in paper I, could be that bosentan reduces both 
the systemic and pulmonary vascular resistances. This could lead to increased cardiac 
output at rest and at low exercise levels, and thus improve daily life functioning, but still 
reduce maximal exercise ability through mechanisms involving even lower oxygen 
saturation at higher exercise levels. The submaximal capacity may be the most relevant 
for daily life functioning, which should be reflected by the symptoms score applied in 
study I. Another explanation for the increased desaturation observed, could be that some 
patients may have deteriorated during the study period, despite treatment with bosentan. 
The patients with ASD in study I-II may be considered as having PAH out of proportion 
(PAH-CSPS, subgroup C) which is increasingly recognized as a more rapidly progressive 
disease, resembling idiopathic PAH. A placebo arm would have facilitated the 
interpretation of the results of study I significantly. And again, desaturation from 
systemically administered vasodilator therapy may be related to disturbed V/Q-
relationship, recently demonstrated in patients with PH related to interstitial lung 
disease(102).This could also apply in PAH-CSPS patients. 
Our data confirm that the measurement method was feasible, as 24 hour SpO2 data could 
be retrieved in all 14 patients, including those who needed postductal sensor placement. 
Foot measurements produced more movement artifacts, and more periods of low signal 
quality had to be taken out of the analysis, but this should apply equally at baseline and 
follow-up.  
The surprisingly large individual day to day SpO2 variation calls for a validation study of 
pulse oximetry in patients with Eisenmenger’s syndrome. We suggest comparing day to 
day standardized measurements, during sleep and awake rest (supine and upright) and 
during a standardized activity such as the 6MW test. This could help establishing a 
reproducible method for clinical oxygen saturation measurements and decision-making. 
Such measurements could be combined with continuous blood pressure measurements, 
serving as an indicator of SVR variation, and heart rate reflecting activity level.  
In summary, SpO2 measurements in patients with Eisenmenger physiology integrate 
many different hemodynamic and respiratory factors into one (SVR, pulmonary vascular 
resistance, cardiac output, pulmonary V-Q relationship, peripheral oxygen extraction). 
This means that additional data are needed for the interpretation of treatment induced 
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oxygen saturation changes. The prognostic importance of (resting) SpO2  in 
Eisenmenger’s syndrome has been documented (103;104). Standardization of 
measurement is absolutely necessary to allow comparison over time. A feasibility and 
reliability study of standardized SpO2 measurements is warranted, and is planned at our 
centre.  
 
5.4 Circulating biomarkers in CSPS and PAH-CSPS 
 
5.4.1 Inflammatory biomarkers 
 
The activity of a disease promoting pathway with its specific ligands and receptors may 
be difficult to assess by blood tests, and a valid and reliable biomarker may be found 
downstream to important disease mechanisms, but still be suitable for clinical use, due to 
its stability in a blood sample or precise measuring method. A potential confounder in 
studies of circulating inflammatory factors as in the present studies, is that both the lungs 
and the heart, and several other organs in the case of Eisenmenger’s syndrome, are 
affected and may release the same biomarkers. Nevertheless, a biomarker that stems from 
multiple organs may still bring information about total disease progression. We sought to 
find new disease markers that could contribute to better understanding of the disease 
development from early through intermediate and to late stages. 
Specific disease markers that describe the stage and degree of vascular remodeling on an 
individual level, could help tailoring therapies and improve selection of those patients in 
the hemodynamic “greyzone” who will benefit from shunt closure.  
 
5.4.2 Hemodynamic classification (study III) 
Of vital importance for the interpretation of paper III is that the hemodynamic groups are 
considered valid. Acknowledging that a true gold standard for Qp/Qs measurement does 
not exist, we considered both the invasive and noninvasive data equally accurate for 
grouping the patients into this simple model with only two categories of flow and 
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pressure load. Further, NTproBNP level has been well documented as a marker of Qp/Qs 
in CSPS  (105;106), but did not correlate with left ventricular end diastolic pressures in 
patients with VSD(107). In our data, as predicted, the NTproBNP values were higher 
with increasing pulmonary artery pressure and flow (figure 2 paper III). A linear 
regression model for NTproBNP level could be fit for the whole group, with flow and 
pressure categories explaining 73 per cent of the NTproBNP variation (p<0.001) . 
However, surprisingly, symptoms of heart failure did not correlate with NTproBNP 
levels. This may be attributed to the low prevalence of such symptoms in the group as a 
whole.  
A further validation of the classification would have implied application of our model on 
a new set of patients to assess the prediction of Qp/Qs, which however was beyond the 
scope of this work. Pulmonary artery pressure estimate by echocardiography is an 
established part of standard clinical assessment, and were accepted as sufficiently precise 
and valid for the categorization without further validation(108). Obviously, some patients 
with borderline PA pressure may have been allocated to the wrong category, but this 
should apply both ways, with no special bias, as lack of Doppler signal from VSD and 
TR jet flow velocity creates opposing errors/bias. The strengths of paper III is that it 
includes healthy controls and has a good size study group without identified selection 
bias. A main methodological limitation is the combination of invasive and non-invasive 
measurements. This may challenge the reader, but can be defended. As an example, a 
patient with an isolated large VSD with a diameter close to, or larger than the aortic root, 
and laminar VSD flow at echocardiography, can without question be categorized as 
having a systolic pulmonary artery pressure above fifty per cent of systolic blood 
pressure. Further, in effort to bring the study closer to the primarily affected organ, 
transpulmonary gradients were calculated.  
 
5.4.3 General inflammatory mechanisms 
As in adult heart failure, a role for inflammatory mechanisms has been demonstrated in 
pediatric non-CSPS related heart failure, i.e cardiomyopathy related heart failure 
(109;110). Looking at paper II and III together, inflammatory markers seem to be of 
limited value in monitoring the early phase of disease, characterized by heart failure 
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induced by volume overload. Partly opposing this, in a recent study comparing cyanotic 
with acyanotic CHD and healthy controls, higher serum IL-6, ghrelin and tnf-α was found 
in the acyanotic group. However, this study was not designed to look specifically at 
factors related to pulmonary overcirculation and heart failure (111), but focused on 
growth failure as a consequence of heart failure.  
On the contrary, based on the inflammatory characteristics of the PAH-CSPS group in 
paper II, circulating inflammation markers may be worthy of further investigation as 
monitoring parameters of manifest pulmonary vascular disease. Finding a marker that 
separates reversible from irreversible disease would be a great achievement. This could 
be realistic, looking at Levy’s findings of periarteriolar inflammatory infiltrates with 
antiapoptotic properties and intimal proliferation in irreversible but not in reversible 
PAH-CSPS(49). Contrarily, Hall S (112) et al  compared lung biopsies in IPAH, PAH-
CSPS and normal lungs, and found that only the IPAH lung specimens had increased 
perivascular inflammatory cell aggregates. Summarized, although the elevated CRP 
levels in PAH-CSPS (paper II) may be epiphenomena in terms of pathophysiology, CRP 
measurement could be worth following up in new studies as a potential parameter of 
vascular inflammation, and with reference to Levy’s findings, of reversibility in PAH-
CSPS. In patients with PAH or tromboembolic PH, CRP level predicts outcome and 
response to therapy(113). CRP measurements were entered as an option in the TOPP 
registry, on our request, after paper II was published. With systematic use, this registry 
may provide data on CRP changes with PAH treatment in children. 
 
5.4.4 Specific inflammatory markers 
 
In paper III, the group with low flow and high pressure (i.e. increased pulmonary 
vascular resistance) could represent an intermediate stage between pulmonary 
overcirculation and Eisenmenger’s syndrome. However, this group had few patients 
(n=5), significant characteristics could not be found, apart from a trend towards a higher 
vWf  (147±118 vs. 111±60 in the low flow and low pressure group, p=0.24) This could 
indicate an activated pulmonary arterial endothelium. Von Willebrand factor increase 
could thus be an early marker of increased pulmonary vascular resistance. In patients 
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with Eisenmenger’s syndrome, von Willebrand factor function is disturbed with 
increased dysfunctional high weight multimer composition (114;115)  
With respect to study III, the possibility of a type two error (failing to reject a false null 
hypothesis) must be considered. Inflammatory mechanisms were expected to be most 
pronounced in the high flow and high pressure group. The number in this group was 
limited, but comparable to the sample in Buchhorn’s study(37). The high flow and high 
pressure group size had 80% power to demonstrate 25% differences with an alpha of 
0,05. Moreover, the combination of a group comparison with healthy controls for the 
patients with the most pronounced hemodynamic load, and a regression model including 
patients with all degrees of shunting, further should reduce the risk of a false negative 
conclusion. It should be mentioned that a recently published growing piglet study 
demonstrated activation of inflammatory mechanisms after six months of aortopulmonary 
shunt flow, primarily related to right ventricular expression of inflammation 
markers(116). 
Osteoprotegerin has been shown to stimulate smooth muscle cell proliferation in adult 
IPAH (117). The elevated osteoprotegerin values in PAH-CSPS (paper II) could indicate 
that smooth muscle cell proliferation still is an active process in the patient population of 
paper II. This specific inflammatory mediator has emerged as a valid marker of vascular 
diseases, involved in matrix regulation and calcium deposition within the vascular 
lesions. Calcium deposition becomes more prominent with time in Eisenmenger’s 
syndrome(118). This makes osteoprotegerin a possible candidate as PAH-CSPS 
assessment tool in advanced disease as well. It has been described, that in some patients 
evaluated as having irreversible PAH, pulmonary vascular resistance normalizes with 
vasodilator therapy(119;120). Smooth muscle cell phenotypic change and proliferation is 
probably more reversible than similar endothelial cell changes (121). With respect to 
circulating markers of vascular change in a study group similar to the one in paper IV, 
elevated circulating fibronectin – a matrix protein involved in migration of SMCs in 
PAH-CSPS, and thus connected to pulmonary vascular remodeling, was found in patients 
with septal defects and exercise induced pulmonary hypertension, possibly indicating 
ongoing vascular remodeling(16). 
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The limitations of studying potential disease mechanisms by samples taken distant from 
the diseased organ have been discussed, but may be considered less important when the 
factors are assessed as markers of patient deterioration or improvement.   
Recently, studies of circulating vascular cells or progenitor cells have consistently been 
found to be associated with PAH-CSPS(122). Importantly, the number of circulating 
endothelial cells could discriminate reversible from irreversible PAH-CSPS, 
hypothesizing an increased shedding and turnover of endothelial cells in the pulmonary 
arterioles of reversible PAH-CSPS. However, analysis of circulating markers of 
endothelial activation, failed to provide a similar differentiation(123). Diller (124) found 
that circulating endothelial progenitor cells were lower in Eisenmenger’s and IPAH, and 
even lower in patients with Down syndrome and Eisenmenger’s(124). Circulating 
inflammatory mediators were increased in this study, supporting that inflammatory 
markers can be important in characterizing irreversible PH disease(124). Patients with 
Down syndrome and CSPS more often develop PAH (125;126).  
In further support of inflammatory mechanisms in PAH development, Yeager et al found 
increased levels of circulating myeloid suppressor cells and fibrocytes in both idiopathic 
and associated pulmonary arterial hypertension including children with CSPS (127;128). 
Fibrocyte numbers were positively correlated with pulmonary hemodynamics. Hassoun 
has recently provided a comprehensive review of the inflammatory mechanisms 
potentially involved in pulmonary vascular remodeling(38). 
 
5.4.5 Down syndrome 
 
We could not demonstrate a relationship between hemodynamic parameters or functional 
status and the inflammatory markers. However, the group of patients with Down 
syndrome, both operable and inoperable, were characterized by an increase of 
inflammatory markers. We speculate that, in addition to lung hypoplasia, deviant immune 
responses, related to trisomy 21, may participate in increasing PAH risk in DS.  This 
warrants further exploration. Studies of preoperatively administered drugs with anti-
inflammatory properties, such as statins, could be of special benefit to patients with 
Down syndrome.  
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5.4.6 Other circulating biomarkers in PAH-CSPS 
 
NTproBNP : 
NTproBNP is established as a prognostic marker in adult PAH of various etiologies. The 
utility of BNP levels as management tool in pediatric PAH was described by Bernus, who 
found large variation in values between patients with similar functional or hemodynamic 
status, thus not being able to define cutoff values(129). However, serial measurements 
over time correlated well with hemodynamic changes. Van Albada studied 29 patients 
with PAH (10 with Eisenmenger’s) median age 7, and found that NTproBNP correlated 
with functional data, 6MW and WHO class(130). NTproBNP decreased with treatment 
and was predictive of mortality. Remarkably, NTproBNP >1664 predicted the two year 
mortality with 100% sensitivity and 94% specificity(130). Lammers’ pediatric data 
showed a good correlation between BNP and functional status but limited prediction of 
mortality or transplantation(131). Diller et al contrarily published that NTproBNP 
predicts survival and reflects therapy in adult Eisenmenger’s syndrome (132). The 
different prognostic value of cardiac peptides in children and adults may be related to the 
phenomenon that right ventricular failure largely determines NTproBNP level, and takes 
many years to develop. NTproBNP also serves as a PAH screening marker in some high 
risk groups, such as patients with systemic sclerosis (133). In these situations NTproBNP 
has good specificity for PAH, but low sensitivity.  
 
Uric acid: 
Uric acid level is regarded as a marker of tissue oxygenation. Van Albada et al found that 
uric acid level correlated with invasive hemodynamic data (mean pulmonary artery 
pressure, pulmonary vascular resistance and cardiac index) in pediatric PH including 
patients with Eisenmenger’s syndrome(130). Uric acid increased during the 12 months of 
our study (paper I) in keeping with a (relative to SVR) possible disease progression with 
decreased exercise capacity, decreased oxygen saturation and possibly increased 
pulmonary vascular resistance increase in our patient group. Some patients with small 
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defects (ASD) and PAH out of proportion were included, who are believed to have a 
worse prognosis than Eisenmenger patients. Again, a placebo arm would have improved 
result interpretation, but the small group size made this a less attractive choice. 
Troponin I  
Troponin I is a prognostic marker in IPAH (134;135). Troponin T served as a marker of 
prognosis and severity of disease in a mixed (non PAH-CSPS) adult group, probably due 
to leak of small amounts of protein from a pressure overloaded right ventricle.  
Norepinephrine  
Norepinephrine was predictive of mortality (ROC 0.84) in a pediatric PAH study (130). 
In conclusion, NTproBNP, Uric acid and possibly norepinephrine have a role in 
monitoring advanced PAH-CSPS and Eisenmenger’s syndrome. These markers are not 
sufficiently validated in the early disease stages. 
 
5.5 Echocardiography in PAH-CSPS 
 
Due to the low reliability of Doppler based estimates of systemic to pulmonary flow 
ratios, especially in the presence of a PDA, little emphasis was put on the 
echocardiographic part of the monitoring protocol in paper I.  No change could be 
demonstrated between follow-ups in technically robust parameters, such as post-tricuspid 
shunt flow velocity. This indicates that Rp/Rs changes may have been too small for 
detection by standard echocardiography. At this time, images were not captured in such a 
way that the new modalities, such as tissue Doppler or strain analysis could be utilized. In 
a future study, a more elaborate echo protocol is warranted, as developments have been 
made. Measurements such as TAPSE, 3D right ventricle volumes with ejection fraction 
(including novel 2D based 3D reconstruction methods(136)), tissue Doppler velocities 
(137) 2D based strain and strain rate of the right ventricle (138), Doppler indices beyond 
the Tei index(139) may provide markers of disease progression. Further, advanced 
echocardiographic methods such as capacitance measurements may bring new 
monitoring parameters in PAH-CSPS treatment (140). However, many initially 
promising methods fail to find their place in clinical use, often due to complexity and 
reproducibility problems (141). Increased stroke volume by echocardiography has been 
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demonstrated in a long term follow up study of patients PAH-CSPS treated with bosentan 
(142). In sum there is ongoing development in echocardiographic assessment of PAH, 
including PAH-CSPS, that makes this a central tool for future studies.  
 
5.6  Exercise-induced pulmonary hypertension assessment 
 
There are some PH related diagnoses, that exclusively can be made during exercise 
studies, such as exercise induced PAH, exercise induced heart failure with preserved 
ejection fraction and preload failure of left ventricle during exercise. As indicated by the 
revised WHO definition, increased right ventricular systolic pressure during exercise still 
is insufficiently understood. Exercise related pulmonary hypertension has been 
demonstrated in different populations, such as patients with systemic sclerosis(71), 
BMPR2 mutation heterozygotes(143), healthy elderly, endurance athletes (144) and 
more. It was recently abandoned as a clinically meaningful entity due to its overlapping 
occurrence in both health and disease, thus not being suitable for clinical decision-
making. Nevertheless, many believe that with further development, the demonstration of 
exercise related pulmonary hypertension can be a useful tool for the early diagnosis of 
PAH. As treatment options improve, an early diagnosis becomes more important(145). 
Exercise echocardiography studies have the potential of screening risk groups non-
invasively for preclinical disease. We have, like other groups, shown that pulmonary 
artery pressure can be estimated reliably during supine bicycling(78;79). One of the 
problems during noninvasive exercise induced pulmonary hypertension assessment, is 
separating increased precapillary and postcapillary resistance, due to difficulties 
measuring left ventricular filling pressures during exercise. Further, detection of an out of 
proportion pulmonary arteriolar constrictive response (Kitajev reflex) to exercise 
increased left atrium pressure is challenging. Invasive exercise studies, as those 
performed at the Massachusetts Great Hospital, referred to at www.phaunivonline.org, 
seem to have overcome some of these issues. The prevalence of exercise related 
pulmonary hypertension among patients with septal defects was first reported in our 
previous paper (16). Elaborating further the understanding of exercise induced pulmonary 
hypertension  mechanisms, paper IV indicate that in ASD and VSD, exercise related 
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pulmonary hypertension occurs at least partly as a consequence of increased left 
ventricular filling pressure. An exaggerated arteriolar constrictive component does not 
seem to be present, because this reflex would be expected to be blunted by sildenafil. 
Obviously, stiff pulmonary arteriolar walls with less dilative capacity and reduced total 
pulmonary vascular crossectional area may contribute in at least some of these patients, 
but this is difficult to measure. The size of the lungs may play a role in all PAH patients, 
and a pulmonary vascular bed area Z-score concept has been suggested. Patients with a 
subnormal area Z-score could be presenting with exercise induced pulmonary 
hypertension. Spirometry data were normal in the paper IV study group. Unpublished 
diffusion capacity data showed a trend towards reduced DLco with sildenafil. As left 
ventricular exercise diastolic dysfunction was suggested as responsible for RVSP 
increase, reduced DLco could be due to some degree of pulmonary congestion from the 
lowering of precapillary resistance by sildenafil, although not significantly affecting the 
RVSP, which is dependent on the achieved cardiac output.  
The strengths of study IV are the randomized placebo controlled design without relevant 
selection bias. A central limitation is the lack of reliable cardiac output measurements and 
invasive hemodynamic data. A higher dose of 100 mg has been applied in some studies, 
but the dose applied in our study of 50 mg has a documented acute effect (91). There was 
no feasibility and reprodocubility testing of the TDI measurements performed in this 
study, but the same method was tested in pediatric heart transplant recipients, with 
acceptable reliability, presented as an abstract at Euroecho 2010 by the author. 
Whether exercise induced pulmonary hypertension in septal defects is a clinically 
relevant condition or will become so with time is still unknown. A cross-sectional study 
in a higher age group after VSD closure is ongoing at our centre in effort to answer some 
of these questions. To summarize, we believe that with further development of methods, 
exercise induced pulmonary hypertension will be reintroduced as a diagnostic entity in 
subsequent revisions of WHO guidelines, with a more precise definition, and with 
exercise echocardiography as a screening tool for monitoring high risk groups with 
predefined PH mechanisms. Further, there is a need for developing noninvasive diastolic 
parameters such as strain based diastolic function, for use during exercise tests.  
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5.7  Invasive hemodynamic data and operability 
 
Heart catheterization with vasodilator testing was not part of the present thesis. However, 
it is a well defined part of the diagnostic work-up of pulmonary hypertension (18), and 
still is the key to evaluation of CSPS operability in the case of “greyzone” pulmonary 
vascular resistance as assessed by echocardiography screening(13). The INOP study 
emphasized the importance of vasoreactivity for operability assessment, applying Rp/Rs 
< 0,33 as operability criterion. Further studies have suggested guidelines (18;146;147). 
A baseline pulmonary vascular resistance index <6 Wood Units/m² with Rp/Rs <0.3 or 
achieving similar numbers during vasodilator challenge, allows for biventricular repair. 
(148). Other authors argue that 4-8 Wood Units is a “grey zone”. With respect to the 
follow up of PAH-CSPS treatment, the place for invasive studies is less clear. There is 
little data on safety of invasive studies in pediatric PAH, but general anesthesia in severe 
PAH-CSPS is considered a risk. No deaths are reported during catheterization in the 
TOPP pediatric PAH registry until date. However, an underreporting would be expected, 
as death during diagnostic catheterization would exclude the patient from the registry. 
With respect to the validity, up to 13 % spontaneous variation of snapshot pulmonary 
vascular resistance measurements has been reported(67). Further, Ohms law and the total 
pulmonary vascular resistance index concept are simplifications, and may need 
supplements, such as capacitance measurement to improve prognostic value (149).  
 
 
5.8 Conventional Radiology in PAH-CSPS 
 
Chest radiograms in patients with PAH show PA contour and dimension. These may 
increase with time, and heart size increases with heart failure development.  Peripheral 
pulmonary vascular markings gradually decrease with disease progression. Calcifications 
of pulmonary arteries may be seen in Eisenmenger’s syndrome(118). Cardiothoracic ratio 
has recently been shown to correlate well with survival in adult PAH (150). Standard 
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radiography is part of clinical assessment but offers little in detailed therapeutic 
monitoring of children. 
 
 
5.9 Electrophysiology 
 
Repeated ECG’s may provide information about changes in right ventricular 
hypertrophy, and including Holter monitoring, is a part of standard clinical PAH 
assessment. However, pediatric data are missing (151;152) with respect to the value of 
ECG’s in the assessment of disease severity and treatment effect. 
 
5.10 Lung function tests 
 
Lung volumes measurement are an important part of initial assessment of susceptibility 
factors such as small lung volumes, but provide little detailed information in further 
assessments of treatment effect. Ventilatory efficiency during exercise testing is a reliable 
parameter that may be related to pulmonary vascular resistance(153). DLco is a surrogate 
for number of functioning alveolocappillary units and may have a place in serial 
assessments, given that the measuring methods are reliable (154). Exhaled nitric oxide 
increased with bosentan treatment in a group consisting mainly of patients with IPAH, 
and could play a role in treatment monitoring(155). 
  
5.11 Advanced radiological imaging 
 
The non-invasive nature of MRI makes it an attractive monitoring tool. Right ventricular 
volumes and ejection fraction have become standard MRI techniques, applicable in IPAH 
patients for the assessment of right ventricle function and provide prognostic 
information(156). Right ventricular geometry correlates with invasive pressure 
measurements (157). However, the availability of MRI is low and smaller children 
require general anesthesia. MRI derived pulmonary artery flow data are feasible in 
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congenital heart disease and can provide detailed hemodynamic data together with 
invasive pressure measurements(158). MRI also allows for assessment of large 
pulmonary artery distensibility, which has been correlated with functional status and 
invasive pulmonary artery pressures(159). Pulmonary angiography: Irreversible change 
as in Heath Edwards III is seen as loss of arborization, tortuosity, narrowing and cutoff of 
small pulm arteries(160). The invasive nature of the technique makes it less attractive as 
follow-up parameter.  
 
5.12 Lung Biopsy: the ultimate gold standard? 
 
Obviously, lung biopsy is one way of looking directly at the PAH disease process and as 
such represents a sort of gold standard. However only regional data are sampled, and as 
illustrated by the present case history, these may be unrepresentative, even at autopsy. 
Multiple lung biopsies are still considered a high risk in patients with PAH. Histological 
classifications have to some degree succeeded at bringing borderline operable patients to 
corrective surgery with good outcome(161), but there is still a fear of false inoperability 
statements, due to the potential lack of representativity for the whole pulmonary vascular 
bed. A lung biopsy is due to its invasive nature and uncertain prognostic value, rarely 
performed, but may be indicated when there is a suspicion of such diseases as pulmonary 
veno-occlusive disease or capillary hemangiomatosis(161). In the case a clear-cut 
reversibility marker was achievable by biopsy, its use could theoretically be re-vitalized 
through less invasive thoracoscopic techniques, for shunt closure decision making in 
patients with “greyzone” pulmonary vascular resistance. 
 
6. Future perspectives 
 
Evaluating hemodynamic changes in patients with PAH-CSPS and especially 
Eisenmenger’s physiology is complex. Short term controlled trials of bosentan in 
Eisenmenger’s Syndrome with open extensions (57;58) have established the indication 
for treatment with bosentan. Similar studies of sildenafil are recently published (63). 
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Most studies demonstrate moderately increased 6MWT. Although closely related to the 
disease process, hemodynamic treatment effects are less consistent. Pulmonary vascular 
resistance index reductions may be minor and accompanied by simultaneously reduced 
SVRI(57). Cardiac output measurements are difficult in patients with Eisenmenger’s 
physiology, but developing these may provide an important key to understanding how the 
new treatment strategies provide symptomatic relief and apparently improved survival in 
patients with PAH-CSPS(103).  To understand the mechanisms behind symptomatic 
improvement in PAH-CSPS, a comprehensive evaluation is still needed, and should 
perhaps also include measurements of cardiac output, peripheral oxygen delivery and 
ventilation perfusion-relationship. A priniciple of enhancing the sensitivity and possibly 
also validity of monitoring parameters, is the assessment of acute responses to stress (e.g. 
exercise induced circulating biomarker change) or to treatment (e.g. acute vasodilator 
induced change in exercise ability or oxygen saturation).  
Assessing vascular reactions during exercise addresses the very core of the patients 
problem: to increase pulmonary blood flow during exercise. A circulating marker that 
either measures vasodilation (endothelium in/dependent) or lack of vasodilation reserve 
could be a candidate for providing a more detailed and pathophysiology-oriented 
assessment of the pulmonary vascular bed.  
Further – the heart is a monitoring target in PAH. right ventricle hypertrophy is an early 
finding, dilation and failure being late phenomena.  The value of parameters reflecting 
RV failure, such as NTproBNP or myocardial leak of Troponins, have both been 
demonstrated, and they are natural candidates for further investigation of cardiac 
responses in PAH-CSPS, including acute stress studies.  
 
 
7. Conclusions 
 
The scientific and clinical consequences of the present thesis can be summarized as 
follows: 
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The monitoring of treatment effects in PAH-CSPS is still under development, and at 
present multimodal, including both noninvasive and invasive measurements.  
 
The referred case report pointed to challenges in providing the critical therapeutic 
monitoring of patients with severe PAH-CSPS.  Paper I emphasizes the utility of well 
standardized and longer term SpO2 measurements in patients with PAH-CSPS.  
Paper II identifies endothelial activation and inflammation involving platelet activation in 
patients with PAH-CSPS. This suggests future trials of drugs with anti-inflammatory 
properties such as statins, or immunomodulators such as imatinib, in patients with PAH-
CSPS. Positive effects have already been documented in other PAH subclasses 
(162;163). Based on the finding of increased CRP in PAH-CSPS group, we suggest that 
CRP should be included in such treatment protocols in parallel to NTproBNP, possibly as 
an expression of inflammatory activity in the vascular lesions. Paper III indicates that 
inflammatory mechanisms are not activated in operable patients with CSPS, and thus that 
cytokines are not candidates for preoperative assessment of pulmonary vascular stress in 
operable patients with CSPS. Studies assessing inflammatory biomarkers in patients with 
CSPS and increased pulmonary vascular resistance, comparing operable and inoperable 
patients, are still warranted.   
Paper IV identified left ventricular diastolic dysfunction during exercise as a possible 
mechanism of exercise induced pulmonary hypertension in patients with VSD, 
suggesting that this is related to left heart filling pressures, rather then pulmonary arterial 
wall changes. This raises questions for further studies: Are these diastolic characteristics 
related to left ventricle myocardial properties that follow the VSD phenotype, or to left 
ventricular myocardial remodeling due to shunt volume load?  Does the timing and 
hemodynamic indication level for VSD closure affect the occurrence of exercise induced 
pulmonary hypertension? Lastly, the absence of effect on peak VO2 by sildenafil 
indicates that the drug has no acute exercise capacity enhancing effect in this group, and 
lends support to its absence from the World Anti Doping Agency black list.  
 
 63 
 
 
 
Reference list 
 
 
 (1)  Brun H, Holmstrom H, Thaulow E. Sudden death during a change in treatment for 
pulmonary hypertension. Cardiology in the Young 15(2):223-5, 2005 Apr. 
 (2)  Abman SH, Ivy DD. Recent progress in understanding pediatric pulmonary 
hypertension. Curr Opin Pediatr 2011 Jun;23(3):298-304. 
 (3)  Heath D, Edwards JE. Pathology of Hypertensive Pulmonary Vascular Disease - 
Description of 6 Grades of Structural Changes in the Pulmonary Arteries with 
Special Reference to Congenital Cardiac Septal Defects. Circulation 
1958;18(4):533-47. 
 (4)  Rabinovitch M, Haworth SG, Castaneda AR, Nadas AS, Reid LM. Lung biopsy 
in congenital heart disease: a morphometric approach to pulmonary vascular 
disease. Circulation 1978 Dec;58(6):1107-22. 
 (5)  Roberts KE, McElroy JJ, Wong WPK, Yen E, Widlitz A, Barst RJ, et al. BMPR2 
mutations in pulmonary arterial hypertension with congenital heart disease. Eur 
Respir J 2004 Sep;24(3):371-4. 
 (6)  Granton JT, Rabinovitch M. Pulmonary arterial hypertension in congenital heart 
disease. Cardiol Clin 2002 Aug;20(3):441-57, vii. 
 (7)  Cherian G, Uthaman CB, Durairaj M, Sukumar IP, Krishnaswami S, Jairaj PS, et 
al. Pulmonary hypertension in isolated secundum atrial septal defect: high 
frequency in young patients. Am Heart J 1983 Jun;105(6):952-7. 
 (8)  Steele PM, Fuster V, Cohen M, Ritter DG, McGoon DC. Isolated atrial septal 
defect with pulmonary vascular obstructive disease--long-term follow-up and 
prediction of outcome after surgical correction. Circulation 1987 Nov;76(5):1037-
42. 
 (9)  Yamaki S, Horiuchi T, Sekino Y. Quantitative analysis of pulmonary vascular 
disease in simple cardiac anomalies with the Down syndrome. Am J Cardiol 1983 
May 15;51(9):1502-6. 
 (10)  Diller GP, Dimopoulos K, Broberg CS, Kaya MG, Naghotra US, Uebing A, et al. 
Presentation, survival prospects, and predictors of death in Eisenmenger 
 64 
syndrome: a combined retrospective and case-control study. Eur Heart J 2006 Jul 
2;27(14):1737-42. 
 (11)  Daliento L, Somerville J, Presbitero P, Menti L, Brach-Prevert S, Rizzoli G, et al. 
Eisenmenger syndrome - Factors relating to deterioration and death. Eur Heart J 
1998 Dec;19(12):1845-55. 
 (12)  Rabinovitch M, Keane JF, Norwood WI, Castaneda AR, Reid L. Vascular 
structure in lung tissue obtained at biopsy correlated with pulmonary 
hemodynamic findings after repair of congenital heart defects. Circulation 1984 
Apr;69(4):655-67. 
 (13)  Balzer DT, Kort HW, Day RW, Corneli HM, Kovalchin JP, Cannon BC, et al. 
Inhaled Nitric Oxide as a Preoperative Test (INOP Test I): the INOP Test Study 
Group. Circulation 2002 Sep 24;106(12 Suppl 1):I76-I81. 
 (14)  Allen H, Driscoll DJ, Shaddy RE, Feltes TF. Moss&Adams' Heart disease in 
infants, children and adolescents. 7th ed. Lippincott, Williams & Wilkins; 2008. 
 (15)  Engelfriet PM, Duffels MG, Moller T, Boersma E, Tijssen JG, Thaulow E, et al. 
Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro 
Heart Survey on adult congenital heart disease. Heart 2007;93(6):682-7. 
 (16)  Moller T, Brun H, Fredriksen PM, Holmstrom H, Peersen K, Pettersen E, et al. 
Right ventricular systolic pressure response during exercise in adolescents born 
with atrial or ventricular septal defect. Am J Cardiol 2010 Jun 1;105(11):1610-6. 
 (17)  Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al. 
Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The 
Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of 
the European Society of Cardiology. Eur Heart J 2004 Dec;25(24):2243-78. 
 (18)  Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. 
Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir 
J 2009 Dec;34(6):1219-63. 
 (19)  Eisenmenger V. Die angeboren defecte der kammerscheidwand des herzens. Z 
klin Med 1897 Jan 1;(32(suppl)):1-28. 
 (20)  WOOD P. The Eisenmenger syndrome or pulmonary hypertension with reversed 
central shunt. Br Med J 1958 Sep 27;2(5099):755-62. 
 (21)  WOOD P. The Eisenmenger syndrome or pulmonary hypertension with reversed 
central shunt.  Br Med J 1958 Sep 20;2(5098):701-9. 
 (22)  McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et 
al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a 
report of the American College of Cardiology Foundation Task Force on Expert 
 65 
Consensus Documents and the American Heart Association developed in 
collaboration with the American College of Chest Physicians; American Thoracic 
Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 
2009 Apr 28;53(17):1573-619. 
 (23)  van Loon RL, Roofthooft MT, van Osch-Gevers M, Delhaas T, Strengers JL, 
Blom NA, et al. Clinical characterization of pediatric pulmonary hypertension: 
complex presentation and diagnosis. J Pediatr 2009 Aug;155(2):176-82. 
 (24)  Cerro MJ, Abman S, Diaz G, Freudenthal AH, Freudenthal F, Harikrishnan S, et 
al. A consensus approach to the classification of pediatric pulmonary hypertensive 
vascular disease: Report from the PVRI Pediatric Taskforce, Panama 2011. Pulm 
Circ 2011;1(2):286-98. 
 (25)  Adatia I, Kothari SS, Feinstein JA. Pulmonary hypertension associated with 
congenital heart disease: pulmonary vascular disease: the global perspective 
. Chest 2010 Jun;137(6 Suppl):52S-61S. 
 (26)  Butrous G, Ghofrani HA, Grimminger F. Pulmonary Vascular Disease in the 
Developing World. Circulation 2008 Oct 21;118(17):1758-66. 
 (27)  Vongpatanasin W, Brickner ME, Hillis LD, Lange RA. The Eisenmenger 
syndrome in adults. Ann Intern Med 1998;128(9):745-55. 
 (28)  Bouzas B, Gatzoulis MA. Pulmonary arterial hypertension in adults with 
congenital heart disease. Rev Esp Cardiol 2005 May;58(5):465-9. 
 (29)  Berger RM, Beghetti M, Humpl T, Raskob GE, Ivy DD, Jing ZC, et al. Clinical 
features of paediatric pulmonary hypertension: a registry study 
1. Lancet 2012 Feb 11;379(9815):537-46. 
 (30)  Barst RJ, Mcgoon MD, Elliott CG, Foreman AJ, Miller DP, Ivy DD. Survival in 
childhood pulmonary arterial hypertension: insights from the registry to evaluate 
early and long-term pulmonary arterial hypertension disease management. 
Circulation 2012 Jan 3;125(1):113-22. 
 (31)  Tamura K, Chen YE, Lopez-Ilasaca M, Daviet L, Tamura N, Ishigami T, et al. 
Molecular mechanism of fibronectin gene activation by cyclic stretch in vascular 
smooth muscle cells. J Biol Chem 2000 Nov 3;275(44):34619-27. 
 (32)  Jones PL, Cowan KN, Rabinovitch M. Tenascin-C, proliferation and 
subendothelial fibronectin in progressive pulmonary vascular disease. Am J 
Pathol 1997;150(4):1349-60. 
 (33)  Lee SD, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tuder RM. 
Monoclonal endothelial cell proliferation is present in primary but not secondary 
pulmonary hypertension. J Clin Invest 1998 Mar 1;101(5):927-34. 
 66 
 (34)  Wojciech J. Int J Mol Med 2008;21(1):99-107. 
 (35)  Gullestad L, Kjekshus J, Damas JK, Ueland T, Yndestad A, Aukrust P. Agents 
targeting inflammation in heart failure. [Review] [100 refs]. Expert Opinion on 
Investigational Drugs 14(5):557-66, 2005 May. 
 (36)  Yndestad A, Damas JK, Oie E, Ueland T, Gullestad L, Aukrust P. Systemic 
inflammation in heart failure--the whys and wherefores. Heart Fail Rev 2006 
Mar;11(1):83-92. 
 (37)  Buchhorn R, Wessel A, Hulpke-Wette M, Bursch J, Werdan K, Loppnow H. 
Endogenous nitric oxide and soluble tumor necrosis factor receptor levels are 
enhanced in infants with congenital heart disease. Crit Care Med 
2001;29(11):2208-10. 
 (38)  Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F, et 
al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll 
Cardiol 2009 Jun 30;54(1 Suppl):S10-S19. 
 (39)  Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary 
arterial hypertension. Eur Respir J 2003 Aug;22(2):358-63. 
 (40)  Price LC, Wort SJ, Perros F, Dorfmuller P, Huertas A, Montani D, et al. 
Inflammation in pulmonary arterial hypertension. Chest 2012 Jan;141(1):210-21. 
 (41)  Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant Endothelial-Cell 
Growth and Elements of Inflammation Are Present in Plexiform Lesions of 
Pulmonary-Hypertension. Am J Pathol 1994 Feb;144(2):275-85. 
 (42)  Kimura H, Okada O, Tanabe N, Tanaka Y, Terai M, Takiguchi Y, et al. Plasma 
monocyte chemoattractant protein-1 and pulmonary vascular resistance in chronic 
thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2001 Jul 
15;164(2):319-24. 
 (43)  Damas JK, Otterdal K, Yndestad A, Aass H, Solum NO, Froland SS, et al. 
Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role 
of the interaction between platelets and endothelial cells. Circulation 2004 Aug 
24;110(8):999-1005. 
 (44)  Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeotkeros L, et al. 
Increased Interleukin-1 and Interleukin-6 Serum Concentrations in Severe 
Primary Pulmonary-Hypertension. Am J Respir Crit Care Med 1995 
May;151(5):1628-31. 
 (45)  Fartoukh M, Emilie D, Le Gall C, Monti G, Simonneau G, Humbert M. 
Chemokine macrophage inflammatory protein-1 alpha mRNA expression in lung 
biopsy specimens of primary pulmonary hypertension. Chest 1998 
Jul;114(1):50S-1S. 
 67 
 (46)  Dorfmuller P, Zarka V, Durand-Gasselin I, Monti G, Balabanian K, Garcia G, et 
al. Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir 
Crit Care Med 2002 Feb 15;165(4):534-9. 
 (47)  Balabanian K, Foussat A, Dorfmuller P, Durand-Gasselin I, Capel F, Bouchet-
Delbos L, et al. CX(3)C chemokine fractalkine in pulmonary arterial 
hypertension. Am J Respir Crit Care Med 2002 May 15;165(10):1419-25. 
 (48)  Sanchez O, Marcos E, Perros F, Fadel E, Tu L, Humbert M, et al. Role of 
Endothelium-derived CC Chemokine Ligand 2 in Idiopathic Pulmonary Arterial 
Hypertension. Am J Respir Crit Care Med 2007 Nov 15;176(10):1041-7. 
 (49)  Levy M, Maurey C, Celermajer DS, Vouhe PR, Danel C, Bonnet D, et al. 
Impaired apoptosis of pulmonary endothelial cells is associated with intimal 
proliferation and irreversibility of pulmonary hypertension in congenital heart 
disease. J Am Coll Cardiol 2007;49(7):803-10. 
 (50)  Sakao S, Taraseviciene-Stewart L, Wood K, Cool CD, Voelkel NF. Apoptosis of 
pulmonary microvascular endothelial cells stimulates vascular smooth muscle cell 
growth. American Journal of Physiology-Lung Cellular and Molecular 
Physiology 2006;291(3):L362-L368. 
 (51)  Pinto RF, Higuchi ML, Aiello VD. Decreased numbers of T-lymphocytes and 
predominance of recently recruited macrophages in the walls of peripheral 
pulmonary arteries from 26 patients with pulmonary hypertension secondary to 
congenital cardiac shunts. Cardiovascular Pathology 2004;13(5):268-75. 
 (52)  Geiger R, Berger RMF, Hess J, Bogers AJJC, Sharma HS, Mooi WJ. Enhanced 
expression of vascular endothelial growth factor in pulmonary plexogenic 
arteriopathy due to congenital heart disease. J Pathol 2000 Jun;191(2):202-7. 
 (53)  Grosjean J, Kiriakidis S, Reilly K, Feldmann M, Paleolog E. Vascular endothelial 
growth factor signalling in endothelial cell survival: a role for NFkappaB. 
Biochem Biophys Res Commun 2006 Feb 17;340(3):984-94. 
 (54)  Lam CF, Peterson TE, Croatt AJ, Nath KA, Katusic ZS. Functional adaptation 
and remodeling of pulmonary artery in flow-induced pulmonary hypertension. 
American Journal of Physiology - Heart and Circulatory Physiology 2005 Dec 
1;289(6):H2334-H2341. 
 (55)  Rondelet B, Kerbaul F, Motte S, van Beneden R, Remmelink M, Brimioulle S, et 
al. Bosentan for the prevention of overcirculation-induced experimental 
pulmonary arterial hypertension. Circulation 2003 Mar 11;107(9):1329-35. 
 (56)  Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary 
hypertension with associated congenital heart defects. Circulation 1999 Apr 
13;99(14):1858-65. 
 68 
 (57)  Galie N, Beghetti M, Gatzoulis M, Granton J, Berger R, Lauer A, et al. Bosentan 
Therapy in patients with Eisenmenger Syndrome. A multicenter, double-blind, 
randomized, placebo-controlled trial. Circulation 2006 Jul 4; 114(1): 48-54. 
 (58)  Gatzoulis MA, Beghetti M, Galie N, Granton J, Berger RM, Lauer A, et al. 
Longer-term bosentan therapy improves functional capacity in Eisenmenger 
syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol 
2008 Jun 23;127(1):27-32. 
 (59)  Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S. Effect of the oral 
endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status 
of patients with pulmonary arterial hypertension related to congenital heart 
disease. Heart 2005 Nov;91(11):1447-52. 
 (60)  Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, S+©ndergaard L. Combination 
therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, 
placebo-controlled, double-blinded trial. Eur Heart J 2010 May 1;31(9):1124-31. 
 (61)  Christensen DD, McConnell ME, Book WM, Mahle WT. Initial experience with 
bosentan therapy in patients with the Eisenmenger syndrome. Am J Cardiol 2004 
Jul 15;94(2):261-3. 
 (62)  Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. 
Sildenafil citrate therapy for pulmonary arterial hypertension. New England 
Journal of Medicine 2005 Nov 17;353(20):2148-57. 
 (63)  Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, et al. A 
randomized, double-blind, placebo-controlled, dose-ranging study of oral 
sildenafil citrate in treatment-naive children with pulmonary arterial hypertension 
1. Circulation 2012 Jan 17;125(2):324-34. 
 (64)  Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, et al. A 
randomized, double-blind, placebo-controlled, dose-ranging study of oral 
sildenafil citrate in treatment-naive children with pulmonary arterial hypertension 
. Circulation 2012 Jan 17;125(2):324-34. 
 (65)  Schuuring MJ, van Riel AC, Bouma BJ, Mulder BJ. Recent progress in treatment 
of pulmonary arterial hypertension due to congenital heart disease. Neth Heart J 
2011 Dec;19(12):495-7. 
 (66)  Oishi P, Datar SA, Fineman JR. Advances in the management of pediatric 
pulmonary hypertension. Respir Care 2011 Sep;56(9):1314-39. 
 (67)  Giglia TM, Humpl T. Preoperative pulmonary hemodynamics and assessment of 
operability: is there a pulmonary vascular resistance that precludes cardiac 
operation?. Pediatr Crit Care Med 2010 Mar;11(2 Suppl):S57-S69. 
 69 
 (68)  Rosenzweig EB, Feinstein JA, Humpl T, Ivy DD. Pulmonary arterial hypertension 
in children: Diagnostic work-up and challenges. Prog Pediatr Cardiol 2009 
Dec;27(1):4-11. 
 (69)  Himelman RB, Stulbarg M, Kircher B, Lee E, Kee L, Dean NC, et al. 
Noninvasive evaluation of pulmonary artery pressure during exercise by saline-
enhanced Doppler echocardiography in chronic pulmonary disease. Circulation 
1989 Apr;79(4):863-71. 
 (70)  Kaplan JD, Foster E, Redberg RF, Schiller NB. Exercise Doppler 
echocardiography identifies abnormal hemodynamics in adults with congenital 
heart disease. Am Heart J 1994 Jun;127(6):1572-80. 
 (71)  Saggar R, Khanna D, Furst DE, Shapiro S, Maranian P, Belperio JA, et al. 
Exercise-induced pulmonary hypertension associated with systemic sclerosis: four 
distinct entities. Arthritis Rheum 2010 Dec;62(12):3741-50. 
 (72)  Oldham WM. Advances in Pulmonary Hypertension 2010;9(2). 
 (73)  Tolle JJ, Waxman AB, Van Horn TL, Pappagianopoulos PP, Systrom DM. 
Exercise-induced pulmonary arterial hypertension. Circulation 2008 Nov 
18;118(21):2183-9. 
 (74)  Saggar R, Lewis GD, Systrom DM, Champion HC, Naeije R, Saggar R. 
Pulmonary vascular responses to exercise: a haemodynamic observation. Eur 
Respir J 2012 Feb;39(2):231-4. 
 (75)  Ross RD, Bollinger RO, Pinsky WW. Grading the severity of congestive heart 
failure in infants. Pediatric Cardiology 1992;13(2):72-5. 
 (76)  Bowyer JJ, Busst CM, Denison DM, Shinebourne EA. Effect of Long-Term 
Oxygen Treatment at Home in Children with Pulmonary Vascular-Disease. 
British Heart Journal 1986 Apr;55(4):385-90. 
 (77)  Stojnic B, Pavlovic P, Ponomarev D, Aleksandrov R, Prcovic M. Bidirectional 
shunt flow across a ventricular septal defect: pulsed Doppler echocardiographic 
analysis. Pediatr Cardiol 1995 Jan;16(1):6-11. 
 (78)  Argiento P, Chesler N, Mule M, D'Alto M, Bossone E, Unger P, et al. Exercise 
stress echocardiography for the study of the pulmonary circulation. Eur Respir J 
2010 Jun;35(6):1273-8. 
 (79)  Moller T, Peersen K, Pettersen E, Thaulow E, Holmstrom H, Fredriksen PM. 
Non-invasive measurement of the response of right ventricular pressure to 
exercise, and its relation to aerobic capacity. Cardiol Young 2009 Sep;19(5):465-
73. 
 70 
 (80)  Burgess MI, Jenkins C, Sharman JE, Marwick TH. Diastolic stress 
echocardiography: hemodynamic validation and clinical significance of 
estimation of ventricular filling pressure with exercise. J Am Coll Cardiol 2006 
May 2;47(9):1891-900. 
 (81)  Garofano RP, Barst RJ. Exercise testing in children with primary pulmonary 
hypertension. Pediatric Cardiology 1999 Jan;20(1):61-4. 
 (82)  Lammers AE, Diller GP, Odendaal D, Tailor S, Derrick G, Haworth SG. 
Comparison of 6-min walk test distance and cardiopulmonary exercise test 
performance in children with pulmonary hypertension. Arch Dis Child 2011 
Feb;96(2):141-7. 
 (83)  Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, et al. Clinical 
correlates and prognostic significance of six-minute walk test in patients with 
primary pulmonary hypertension. Comparison with cardiopulmonary exercise 
testing. Am J Respir Crit Care Med 2000 Feb;161(2 Pt 1):487-92. 
 (84)  Yetman AT, Taylor AL, Doran A, Ivy DD. Utility of cardiopulmonary stress 
testing in assessing disease severity in children with pulmonary arterial 
hypertension. Am J Cardiol 2005 Mar 1;95(5):697-9. 
 (85)  Fredriksen PM, Ingjer F, Nystad W, Thaulow E. Aerobic endurance testing of 
children and adolescents--a comparison of two treadmill-protocols. Scand J Med 
Sci Sports 1998 Aug;8(4):203-7. 
 (86)  Sandoval J, Alvarado P, Martinez-Guerra ML, Gomez A, Palomar A, Meza S, et 
al. Effect of body position changes on pulmonary gas exchange in Eisenmenger's 
syndrome. Am J Respir Crit Care Med 1999 Apr;159(4 Pt 1):1070-3. 
 (87)  Moller T, Brun H, Fredriksen PM, Holmstrom H, Pettersen E, Thaulow E. 
Moderate altitude increases right ventricular pressure and oxygen desaturation in 
adolescents with surgically closed septal defect. Congenit Heart Dis 2010 
Nov;5(6):556-64. 
 (88)  Holmstrom H, Hall C, Thaulow E. Plasma levels of natriuretic peptides and 
hemodynamic assessment of patent ductus arteriosus in preterm infants. Acta 
Paediatr 2001 Feb;90(2):184-91. 
 (89)  Nagaya N, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Nakanishi N, et al. 
Serum uric acid levels correlate with the severity and the mortality of primary 
pulmonary hypertension. American Journal of Respiratory & Critical Care 
Medicine 160(2):487-92, 1999 Aug. 
 (90)  Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A, et al. 
Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with 
pulmonary arterial hypertension. Clinical Pharmacology & Therapeutics 2003 
Apr;73(4):372-82. 
 71 
 (91)  Lepore JJ, Maroo A, Bigatello LM, Dec GW, Zapol WM, Bloch KD, et al. 
Hemodynamic effects of sildenafil in patients with congestive heart failure and 
pulmonary hypertension: combined administration with inhaled nitric oxide 
 Chest 2005 May;127(5):1647-53. 
 (92)  Galie N, Beghetti M, Gatzoulis MA, Granton J, Berger RMF, Lauer A, et al. 
Bosentan Therapy in Patients With Eisenmenger Syndrome: A Multicenter, 
Double-Blind, Randomized, Placebo-Controlled Study. Circulation 2006 Jul 
4;114(1):48-54. 
 (93)  Lammers AE, Adatia I, Cerro MJ, Diaz G, Freudenthal AH, Freudenthal F, et al. 
Functional classification of pulmonary hypertension in children: Report from the 
PVRI pediatric taskforce, Panama 2011. Pulm Circ 2011 Aug 2;1(2):280-5. 
 (94)  Bittner V, Weiner DH, Yusuf S, Rogers WJ, McIntyre KM, Bangdiwala SI, et al. 
Prediction of mortality and morbidity with a 6-minute walk test in patients with 
left ventricular dysfunction. SOLVD Investigators. JAMA 1993 Oct 
13;270(14):1702-7. 
 (95)  Lammers AE, Hislop AA, Flynn Y, Haworth SG. The 6-minute walk test: normal 
values for children of 4-11 years of age. Arch Dis Child 2008 Jun;93(6):464-8. 
 (96)  Geiger R, Strasak A, Treml B, Gasser K, Kleinsasser A, Fischer V, et al. Six-
minute walk test in children and adolescents. J Pediatr 2007 Apr;150(4):395-9, 
399. 
 (97)  Poh H, Eastwood PR, Cecins NM, Ho KT, Jenkins SC. Six-minute walk distance 
in healthy Singaporean adults cannot be predicted using reference equations 
derived from Caucasian populations. Respirology 2006 Mar;11(2):211-6. 
 (98)  Li AM, Yin J, Au JT, So HK, Tsang T, Wong E, et al. Standard reference for the 
six-minute-walk test in healthy children aged 7 to 16 years. Am J Respir Crit Care 
Med 2007 Jul 15;176(2):174-80. 
 (99)  Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH. Interpreting small 
differences in functional status: the Six Minute Walk test in chronic lung disease 
patients. Am J Respir Crit Care Med 1997 Apr;155(4):1278-82. 
 (100)  Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, et al. 
Phosphodiesterase type 5 is highly expressed in the hypertrophied human right 
ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. 
Circulation 2007;116(3):238-48. 
 (101)  Traustason S, Jensen AS, Arvidsson HS, Munch IC, Sondergaard L, Larsen M. 
Retinal oxygen saturation in patients with systemic hypoxemia. Invest 
Ophthalmol Vis Sci 2011 Jul;52(8):5064-7. 
 72 
 (102)  Le PJ, Girgis RE, Lechtzin N, Mathai SC, Launay D, Hummers LK, et al. 
Systemic sclerosis-related pulmonary hypertension associated with interstitial 
lung disease: impact of pulmonary arterial hypertension therapies. Arthritis 
Rheum 2011 Aug;63(8):2456-64. 
 (103)  Dimopoulos K, Inuzuka R, Goletto S, Giannakoulas G, Swan L, Wort SJ, et al. 
Improved survival among patients with Eisenmenger syndrome receiving 
advanced therapy for pulmonary arterial hypertension. Circulation 2010 Jan 
5;121(1):20-5. 
 (104)  Diller GP, onso-Gonzalez R, Dimopoulos K, varez-Barredo M, Koo C, Kempny 
A, et al. Disease targeting therapies in patients with Eisenmenger syndrome: 
Response to treatment and long-term efficiency. Int J Cardiol 2012 Mar 3. 
 (105)  Uz O, Aparci M, Acar G, Kardesoglu E, Kaplan O, Yiginer O, et al. Association 
of plasma B-type natriuretic peptide levels with shunt size in young adults with 
atrial septal defect. Echocardiography 2011 Feb;28(2):243-7. 
 (106)  Ozhan H, Albayrak S, Uzun H, Ordu S, Kaya A, Yazici M. Correlation of plasma 
B-type natriuretic peptide with shunt severity in patients with atrial or ventricular 
septal defect. Pediatr Cardiol 2007 Jul;28(4):272-5. 
 (107)  Oyamada J, Toyono M, Shimada S, oki-Okazaki M, Tamura M, Takahashi T, et 
al. Noninvasive estimation of left ventricular end-diastolic pressure using tissue 
Doppler imaging combined with pulsed-wave Doppler echocardiography in 
patients with ventricular septal defects: a comparison with the plasma levels of the 
B-type natriuretic Peptide. Echocardiography 2008 Mar;25(3):270-7. 
 (108)  Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure 
by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984 
Oct;70(4):657-62. 
 (109)  Hsu DT, Pearson GD. Heart failure in children: part I: history, etiology, and 
pathophysiology. Circ Heart Fail 2009 Jan;2(1):63-70. 
 (110)  Ratnasamy C, Kinnamon DD, Lipshultz SE, Rusconi P. Associations between 
neurohormonal and inflammatory activation and heart failure in children. Am 
Heart J 2008 Mar;155(3):527-33. 
 (111)  Afify MF, Mohamed GB, El-Maboud MA, bdel-Latif EA. Serum levels of 
ghrelin, tumor necrosis factor-alpha and interleukin-6 in infants and children with 
congenital heart disease. J Trop Pediatr 2009 Dec;55(6):388-92. 
 (112)  Hall S, Brogan P, Haworth SG, Klein N. Contribution of inflammation to the 
pathology of idiopathic pulmonary arterial hypertension in children. Thorax 2009 
Sep;64(9):778-83. 
 73 
 (113)  Quarck R, Nawrot T, Meyns B, Delcroix M. C-reactive protein: a new predictor 
of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol 2009 
Apr 7;53(14):1211-8. 
 (114)  Rabinovitch M, Andrew M, Thom H, Trusler GA, Williams WG, Rowe RD, et al. 
Abnormal endothelial factor VIII associated with pulmonary hypertension and 
congenital heart defects. Circulation 1987 Nov;76(5):1043-52. 
 (115)  Caramuru LH, Soares RP, Maeda NY, Lopes AA. Hypoxia and altered platelet 
behavior influence von Willebrand factor multimeric composition in secondary 
pulmonary hypertension. Clinical & Applied Thrombosis/Hemostasis 9(3):251-8, 
2003 Jul. 
 (116)  Rondelet B, Dewachter C, Kerbaul F, Kang X, Fesler P, Brimioulle S, et al. 
Prolonged overcirculation-induced pulmonary arterial hypertension as a cause of 
right ventricular failure. Eur Heart J 2012 Apr;33(8):1017-26. 
 (117)  Lawrie A, Waterman E, Southwood M, Evans D, Suntharalingam J, Francis S, et 
al. Evidence of a Role for Osteoprotegerin in the Pathogenesis of Pulmonary 
Arterial Hypertension. Am J Pathol 2007 Dec 21;172(1):256-64. 
 (118)  Perloff JK, Hart EM, Greaves SM, Miner PD, Child JS. Proximal pulmonary 
arterial and intrapulmonary radiologic features of Eisenmenger syndrome and 
primary pulmonary hypertension. Am J Cardiol 2003 Jul 15;92(2):182-7. 
 (119)  Dimopoulos K, Peset A, Gatzoulis MA. Evaluating operability in adults with 
congenital heart disease and the role of pretreatment with targeted pulmonary 
arterial hypertension therapy. Int J Cardiol 2008 Sep 26;129(2):163-71. 
 (120)  Huang JB, Liang J, Zhou LY. Eisenmenger Syndrome: Not Always Inoperable 
. Respir Care 2012 Feb 17. 
 (121)  Sakao S, Tatsumi K, Voelkel NF. Reversible or irreversible remodeling in 
pulmonary arterial hypertension Am J Respir Cell Mol Biol 2010 Dec;43(6):629-
34. 
 (122)  Smadja DM, Gaussem P, Mauge L, Israel-Biet D, gnat-George F, Peyrard S, et al. 
Circulating endothelial cells: a new candidate biomarker of irreversible 
pulmonary hypertension secondary to congenital heart disease. Circulation 2009 
Jan 27;119(3):374-81. 
 (123)  Smadja DM, Gaussem P, Mauge L, Lacroix R, Gandrille S, Remones V, et al. 
Comparison of endothelial biomarkers according to reversibility of pulmonary 
hypertension secondary to congenital heart disease. Pediatr Cardiol 2010 
Jul;31(5):657-62. 
 74 
 (124)  Diller GP, van ES, Okonko DO, Howard LS, Ali O, Thum T, et al. Circulating 
endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic 
pulmonary arterial hypertension. Circulation 2008 Jun 10;117(23):3020-30. 
 (125)  Park SC, Mathews RA, Zuberbuhler JR, Rowe RD, Neches WH, Lenox CC. 
Down Syndrome with Congenital Heart Malformation. Am J Dis Child 
1977;131(1):29-33. 
 (126)  Chi TPL. The pulmonary vascular bed in children with Down syndrome. J Pediatr 
1975 Apr;86(4):533-8. 
 (127)  Yeager ME, Nguyen CM, Belchenko DD, Colvin KL, Takatsuki S, Ivy DD, et al. 
Circulating Myeloid Derived Suppressor Cells Are Increased and Activated in 
Pulmonary Hypertension. Chest 2011 Sep 22. 
 (128)  Yeager ME, Nguyen CM, Belchenko DD, Colvin KL, Takatsuki S, Ivy DD, et al. 
Circulating fibrocytes are increased in children and young adults with pulmonary 
hypertension. Eur Respir J 2012 Jan;39(1):104-11. 
 (129)  Bernus A, Wagner BD, Accurso F, Doran A, Kaess H, Ivy DD. Brain natriuretic 
peptide levels in managing pediatric patients with pulmonary arterial hypertension 
. Chest 2009 Mar;135(3):745-51. 
 (130)  Van Albada ME, Loot FG, Fokkema R, Roofthooft MT, Berger RM. Biological 
serum markers in the management of pediatric pulmonary arterial hypertension 
. Pediatr Res 2008 Mar;63(3):321-7. 
 (131)  Lammers AE, Hislop AA, Haworth SG. Prognostic value of B-type natriuretic 
peptide in children with pulmonary hypertension. Int J Cardiol 2009 Jun 
12;135(1):21-6. 
 (132)  Diller GP, onso-Gonzalez R, Kempny A, Dimopoulos K, Inuzuka R, 
Giannakoulas G, et al. B-type natriuretic peptide concentrations in contemporary 
Eisenmenger syndrome patients: predictive value and response to disease 
targeting therapy. Heart 2012 Mar 7. 
 (133)  Cavagna L, Caporali R, Klersy C, Ghio S, Albertini R, Scelsi L, et al. Comparison 
of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary 
arterial hypertension in patients with systemic sclerosis. J Rheumatol 2010 
Oct;37(10):2064-70. 
 (134)  Torbicki A, Kurzyna M, Kuca P, Fijalkowska A, Sikora J, Florczyk M, et al. 
Detectable serum cardiac troponin T as a marker of poor prognosis among 
patients with chronic precapillary pulmonary hypertension. Circulation 2003 Aug 
19;108(7):844-8. 
 75 
 (135)  Filusch A, Giannitsis E, Katus HA, Meyer FJ. High-sensitive troponin T: a novel 
biomarker for prognosis and disease severity in patients with pulmonary arterial 
hypertension. Clin Sci (Lond) 2010 Sep;119(5):207-13. 
 (136)  Kutty S, Li L, Polak A, Gribben P, Danford DA. Echocardiographic knowledge-
based reconstruction for quantification of the systemic right ventricle in young 
adults with repaired D-transposition of great arteries. Am J Cardiol 2012 Mar 
15;109(6):881-8. 
 (137)  Lammers AE, Haworth SG, Riley G, Maslin K, Diller GP, Marek J. Value of 
Tissue Doppler Echocardiography in Children with Pulmonary Hypertension 
. J Am Soc Echocardiogr 2012 Feb 24. 
 (138)  Sachdev A, Villarraga HR, Frantz RP, Mcgoon MD, Hsiao JF, Maalouf JF, et al. 
Right ventricular strain for prediction of survival in patients with pulmonary 
arterial hypertension. Chest 2011 Jun;139(6):1299-309. 
 (139)  Alkon J, Humpl T, Manlhiot C, McCrindle BW, Reyes JT, Friedberg MK. 
Usefulness of the Right Ventricular Systolic to Diastolic Duration Ratio to Predict 
Functional Capacity and Survival in Children With Pulmonary Arterial 
Hypertension. The American Journal of Cardiology 2010 Aug 1;106(3):430-6. 
 (140)  Friedberg MK, Feinstein JA, Rosenthal DN. Noninvasive assessment of 
pulmonary arterial capacitance by echocardiography. J Am Soc Echocardiogr. 
 (141)  Shandas R, Weinberg C, Ivy DD, Nicol E, DeGroff CG, Hertzberg J, et al. 
Development of a noninvasive ultrasound color M-mode means of estimating 
pulmonary vascular resistance in pediatric pulmonary hypertension - 
Mathematical analysis, in vitro validation, and preliminary clinical studies. 
Circulation 2001 Aug 21;104(8):908-13. 
 (142)  Vis JC, Duffels MG, Mulder P, de Bruin-Bon RH, Bouma BJ, Berger RM, et al. 
Prolonged beneficial effect of bosentan treatment and 4-year survival rates in 
adult patients with pulmonary arterial hypertension associated with congenital 
heart disease. Int J Cardiol 2011 Jun 30. 
 (143)  Grunig E, Janssen B, Mereles D, Barth U, Borst MM, Vogt IR, et al. Abnormal 
pulmonary artery pressure response in asymptomatic carriers of primary 
pulmonary hypertension gene. Circulation 2000 Sep 5;102(10):1145-50. 
 (144)  D'Andrea A, Naeije R, D'Alto M, Argiento P, Golia E, Cocchia R, et al. Range in 
pulmonary artery systolic pressure among highly trained athletes. Chest 2011 
Apr;139(4):788-94. 
 (145)  Galie N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, et al. Treatment of 
patients with mildly symptomatic pulmonary arterial hypertension with bosentan 
(EARLY study): a double-blind, randomised controlled trial. Lancet 2008 Jun 
21;371(9630):2093-100. 
 76 
 (146)  van Albada ME, Berger RMF. Pulmonary arterial hypertension in congenital 
cardiac disease ? the need for refinement of the Evian-Venice classification. 
Cardiol Young 2008;18(01):10-7. 
 (147)  Schulze-Neick I, Beghetti M. Classifying pulmonary hypertension in the setting 
of the congenitally malformed heart ? cleaning up a dog?s dinner. Cardiol Young 
2008;18(01):22-5. 
 (148)  Lopes AA, O'Leary PW. Measurement, interpretation and use of haemodynamic 
parameters in pulmonary hypertension associated with congenital cardiac disease 
. Cardiol Young 2009 Sep;19(5):431-5. 
 (149)  Sajan I, Manlhiot C, Reyes J, McCrindle BW, Humpl T, Friedberg MK. 
Pulmonary arterial capacitance in children with idiopathic pulmonary arterial 
hypertension and pulmonary arterial hypertension associated with congenital heart 
disease: relation to pulmonary vascular resistance, exercise capacity, and survival 
. Am Heart J 2011 Sep;162(3):562-8. 
 (150)  Dimopoulos K, Giannakoulas G, Bendayan I, Liodakis E, Petraco R, Diller GP, et 
al. Cardiothoracic ratio from postero-anterior chest radiographs: A simple, 
reproducible and independent marker of disease severity and outcome in adults 
with congenital heart disease. Int J Cardiol 2011 Dec 1. 
 (151)  Kanemoto N. Electrocardiogram in primary pulmonary hypertension. Eur J 
Cardiol 1981;12(3-4):181-93. 
 (152)  Ahearn GS, Tapson VF, Rebeiz A, Greenfield JC, Jr. Electrocardiography to 
define clinical status in primary pulmonary hypertension and pulmonary arterial 
hypertension secondary to collagen vascular disease. Chest 2002 Aug;122(2):524-
7. 
 (153)  Reybrouck T, Mertens L, Schulze-Neick I, Austenat I, Eyskens B, Dumoulin M, 
et al. Ventilatory inefficiency for carbon dioxide during exercise in patients with 
pulmonary hypertension. Clin Physiol 1998 Jul;18(4):337-44. 
 (154)  Narang I, Bush A, Rosenthal M. Gas transfer and pulmonary blood flow at rest 
and during exercise in adults 21 years after preterm birth 
. Am J Respir Crit Care Med 2009 Aug 15;180(4):339-45. 
 (155)  Girgis RE, Champion HC, Diette GB, Johns RA, Permutt S, Sylvester JT. 
Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to 
bosentan therapy. Am J Respir Crit Care Med 2005 Aug 1;172(3):352-7. 
 (156)  van Wolferen SA, Marcus JT, Boonstra A, Marques KM, Bronzwaer JG, 
Spreeuwenberg MD, et al. Prognostic value of right ventricular mass, volume, and 
function in idiopathic pulmonary arterial hypertension. Eur Heart J 2007 
May;28(10):1250-7. 
 77 
 (157)  Dellegrottaglie S, Sanz J, Poon M, Viles-Gonzalez JF, Sulica R, Goyenechea M, 
et al. Pulmonary hypertension: accuracy of detection with left ventricular septal-
to-free wall curvature ratio measured at cardiac MR. Radiology 2007 
Apr;243(1):63-9. 
 (158)  Muthurangu V, Atkinson D, Sermesant M, Miquel ME, Hegde S, Johnson R, et 
al. Measurement of total pulmonary arterial compliance using invasive pressure 
monitoring and MR flow quantification during MR-guided cardiac 
catheterization. American Journal of Physiology - Heart and Circulatory 
Physiology 2005 Sep 1;289(3):H1301-H1306. 
 (159)  Kang KW, Chang HJ, Kim YJ, Choi BW, Lee HS, Yang WI, et al. Cardiac 
magnetic resonance imaging-derived pulmonary artery distensibility index 
correlates with pulmonary artery stiffness and predicts functional capacity in 
patients with pulmonary arterial hypertension. Circ J 2011;75(9):2244-51. 
 (160)  Rabinovitch M, Keane JF, Fellows KE, Castaneda AR, Reid L. Quantitative-
Analysis of the Pulmonary Wedge Angiogram in Congenital Heart-Defects - 
Correlation with Hemodynamic Data and Morphometric Findings in Lung-Biopsy 
Tissue. Circulation 1981;63(1):152-64. 
 (161)  Wagenvoort CA. Lung biopsy specimens in the evaluation of pulmonary vascular 
disease. Chest 1980 May;77(5):614-25. 
 (162)  Taraseviciene-Stewart L, Scerbavicius R, Choe KH, Cool C, Wood K, Tuder RM, 
et al. Simvastatin Causes Endothelial Cell Apoptosis and Attenuates Severe 
Pulmonary Hypertension. Am J Physiol Lung Cell Mol Physiol 2006 May 
12;291(4):L 668-L 676. 
 (163)  Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, et 
al. Imatinib in pulmonary arterial hypertension patients with inadequate response 
to established therapy. Am J Respir Crit Care Med 2010 Nov 1;182(9):1171-7. 
 
 
Paper I – IV.................................................................................... 
 

I

Original Article
Cardiol Young 2007; 17: 288–294
© Cambridge University Press
ISSN 1047-9511
doi: 10.1017/S1047951107000522
PULMONARY ARTERIAL HYPERTENSION REMAINSan important factor for morbidity and mortal-ity in patients with congenital cardiac defects.
Among the new medical therapies for pulmonary
arterial hypertension, the oral dual endothelin receptor
antagonist, Bosentan (Actelion Pharmaceuticals Ltd.,
Allschwil, Switzerland), has gained a central position.
Long-term improvement of both symptoms and
haemodynamic data,1–3 and improved survival,4 is
documented in adults with idiopathic pulmonary arte-
rial hypertension and some forms of secondary pul-
monary arterial hypertension. In children, congenital
systemic-to-pulmonary arterial shunts represent an
important aetiology of pulmonary arterial hyperten-
sion. Eisenmenger’s syndrome shares both clinical,
histopathological, and pathophysiological properties
with idiopathic pulmonary arterial hypertension.5
The open shunt, however, represents a significant
haemodynamic difference, and the natural history is
more favourable than for idiopathic pulmonary arte-
rial hypertension.6–8 The role of new medical thera-
pies against pulmonary arterial hypertension for
patients with Eisenmenger’s syndrome is not yet
established, although preliminary uncontrolled short
term studies show some benefits.9–12 A short-term
safety study in children not including patients with
Eisenmenger’s syndrome demonstrated haemo-
dynamic improvement.13 A retrospective study includ-
ing 24 children with unoperated cardiac defects
demonstrated clinical and haemodynamic improve-
ment from treatment with Bosentan at a mean of 14
months, but there was no separate analysis of the
subgroup with Eisenmenger’s syndrome.14 Our pres-
ent study, therefore, aims to describe the effects of
Bosentan over the intermediate term in children and
adolescents with Eisenmenger physiology. Our pri-
mary hypothesis was that a selective reduction of
pulmonary vascular resistance would decrease the
degree of desaturation. Our secondary aim was to
search for other non-invasive variables that might
prove valuable in the monitoring of treatment in
patients with Eisenmenger’s syndrome.
Material and methods
We define Eisenmenger’s syndrome as a systemic-to-
pulmonary shunt permitting reversed or bidirec-
tional flow due to high pulmonary vascular resistance.
We included patients with both pre- and post-tricuspid
lesions if they satisfied our definition. The indica-
tions for treatment ranged from the possibility for
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cure and corrective operation in the younger and less
symptomatic patients, to relief of symptoms in those
most affected. We identified 14 patients with the
syndrome as thus defined referred for evaluation at a
tertiary centre over the years 2003 and 2004, and all
agreed to participate in the study. Informed consent
was obtained from all patients or their providers of
care. The patients were in a clinically stable condi-
tion at enrolment. No change had been made to their
medical treatment over the preceding 12 months.
Of the 14 patients, 11 had undergone catheterization
of the right heart with vasodilator testing prior to
treatment. The ratio of pulmonary to systemic vas-
cular resistances at baseline ranged from 0.36 to 1.0,
with a mean of 0.6, and was at the time considered a
contraindication for surgical treatment. Demographic
and clinical data at baseline are presented in Table 1.
Design of the study
The study was prospective, uncontrolled, single cen-
tre, open-label, and performed during the period
from 2003 to 2005. After the baseline examinations,
treatment was started with Bosentan at 1 milligram
per kilogram twice daily, increasing to 2 milligrams
per kilo twice daily after four weeks. Initiation and
control of treatment was done in-hospital. In this
way, physical activity was held at a controlled and
low level. Patients were re-examined at one, three,
six, nine and 12 months. At all visits, clinical exam-
ination, echocardiography, electrocardiogram, 24 hour
pulse oximetry, blood tests and a symptom score
were performed in all patients. In the 6 patients able
to exercise, treadmill testing was performed. The
study was approved by the local ethics committee
and conducted in agreement with the Helsinki dec-
laration of 1975, revised in 1983.
Pulse oximetry
Peripheral transcutaneous saturations of oxygen
were measured distal to the shunt for 24 hours, using
Masimo SET® (USA) pulse oximeters. Saturation and
pulse data were analysed with Download 2001®
(UK) software. For each 24 hour measurement, the
following parameters were calculated: mean oxygen
saturation, median oxygen saturation with 5th and
95th percentiles and mean heart rate. The 5th per-
centiles were assumed to reflect activity related
desaturations. The 95th percentile was assumed to
represent maximal saturation. The range between
5th and 95th percentiles was registered as a parameter
of variation in the saturations of oxygen. Similar values
were calculated for 6 hour sleep samples from the
same registration. Sleep was identified by a stable, low
heart rate at night time.
Clinical assessment and laboratory values
In addition to a standard clinical examination, symp-
toms were registered according to a five issues score
for symptoms of childhood pulmonary hyperten-
sion.15 The score of each issue ranges from one to
four points. The lowest possible sum of five points
represents serious disability, whereas the highest
score of 20 points corresponds to normal exercise
ability. Functional class was registered according to
the World Health Organization adaptation of the
New York Heart Association classification of heart
failure. Haematological parameters, and a set of
Table 1. Baseline demographic and clinical data.
Patient 24 hours oxygen saturation 
number Sex Age at inclusion Diagnoses Weight (kg) WHO class (median and 5 and 95 percentile)
1 m 7 DS, VSD, PAD 22 2 95 (91–97)
2 m 9 DS, AVSD 20 2 94 (91–97)
3 f 10 Large PAD 21 2 97 (96–99)
4 m 7 AVSD 20 3 83 (75–86)
5 f 17 Large PAD 55 2 86 (64–93)
6 f 18 Residual VSD 50 3 77 (63–83)
7 m 11 DS, large PAD 2 93 (87–97)
8 f 11 ASD 22 3 87 (81–92)
9 f 13 DS, VSD 51 2 98 (94–99)
10 f 6 ASD 15 2 98 (96–99)
11 f 13 AVSD 30 2 91 (84–93)
12 m 10 Residual VSD 29 2 92 (86–95)
13 m 7 DS, ASD, VSD, PAD 18 2 91 (86–95)
14 f 3 Large PAD 13,1 2 98 (96–99)
Abbreviations: DS: Down’s syndrome; VSD: ventricular septal defect; PAD: persistent patency of arterial duct; AVSD: atrioventricular septal defect;
ASD: atrial septal defect
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standard blood tests including uric acid analysis and
natriuretic peptides (Nt-proANP or Nt-proBNP),
were performed at all controls. Liver enzymes were
checked at monthly intervals as required for treatment
with Bosentan.
Echocardiography
A standard echocardiographic assessment was done
at all visits, including estimation of chamber areas
and deviation of the ventricular septum where appli-
cable. The maximal velocities of the jets from tricuspid
and pulmonary regurgitation were registered, as well
as the direction, timing, and velocity of flow across
the shunt.
Exercise testing
We were able to perform a treadmill test in 6 patients,
with measurement of peak uptake of oxygen. Young
age, and presence of Down’s syndrome, were the lim-
itations in the remaining 8 patients. Testing was done
by a specially trained physiotherapist and the same
cardiologist at all assessments. The tests were con-
ducted to volitional fatigue on treadmill (Technogym,
Italy), using the Oslo-protocol for children.16 Uptake
of oxygen was assessed by an oxygen analyzer
(SensorMedics Vmax 229, USA). Electrocardiograms
were recorded during the tests using Siemens
Megachart (Germany).
Statistics
All values are reported as means plus or minus stan-
dard deviations. The differences between findings at
baseline and after 12 months of treatment were
analysed by use of single sample t-tests, with a level
of significance of 0.05. The relationship between
changes in symptoms and saturations of oxygen was
investigated with linear regression. With respect to
the limited number of participants, no statistical
analyses were performed for the results at three, six
and nine months. The values at six months are, how-
ever, included in the figures.
Results
Clinical data
Of the children, 6 were males, and five had Down’s
syndrome. Except for 3 patients with atrioventricular
septal defects, all had simple defects, as described in
Table 1. Surgery had been previously performed in 2
patients to close ventricular septal defects, but both
patients had non-restrictive residual shunts. All
patients survived to the last follow-up. At enrol-
ment, one patient was receiving captopril, and two
others digoxin. The fourth patient had hepatic
enlargement, but no other signs of right ventricular
failure. The tenth patient received nebulized iloprost
after nine months of treatment with Bosentan. No
other change of supplementary medication was made
during the period of study, and none received supple-
mentary oxygen. No significant increment of hepatic
enzymes was registered. The second patient reported
persistent nasal congestion. He developed obstructive
sleep apnoea and worsened general condition at nine
months, with nocturnal desaturation. No improve-
ment was seen with reduced doses, but the symptoms
disappeared after cessation of treatment at 12 months.
No other serious side effects were seen. Diastolic blood
pressure declined by 10 plus or minus 11.2 millimetres
of mercury (p is equal to 0.009) following treatment
with Bosentan. There was no change of systolic blood
pressure (p is equal to 0.9).
Symptoms
All patients but the second reported either improve-
ment, in 8 cases, or stayed stable, as in the remaining
5 in regard to symptoms from baseline to 12 months
follow up. Improvement was seen in 3 of the 5 children
with Down’s syndrome. The pulmonary hypertension
symptom score increased from baseline to 12 months
by 2.7 plus or minus 3.3 (p is equal to 0.009). The
individual changes are shown in Figure 1, and the
scores of the different issues of the questionnaire are
presented in Table 2. Significant improvement was seen
for the flat walking and tiredness subscores, and a
positive trend was seen for walking stairs. The fourth
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Figure 1.
Individual changes of the total pulmonary hypertension symptom
score at baseline, and after 6, and 12, months of treatment. 
A higher score signifies fewer symptoms.
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patient improved from functional class 3 to 2 as graded
using the system of the World Health Organization.
Exemplary cases
Our fourth patient was a boy, aged seven years, with
uncorrected atrioventricular septal defect, severe
hypoxaemia, and erythrocytosis. Before treatment, his
mother carried him from ground to first floor at
home due to dyspnoea. After treatment with Bosentan,
he could run the same distance, and had abandoned
the wheelchair for everyday use. Former headaches
and large mood variations had disappeared. Previous
attendance at school had been no more than half-time,
but with Bosentan he could attend school throughout
the day. During the same period, peak uptake of oxy-
gen during treadmill testing declined from 83 to 66
millilitres per 0.67 kilo. His mean saturation over
24 hours remained unchanged during the period of
study, but his mean saturation over six hours of sleep
declined from 96% to 90%. Selective daytime increase
could explain these findings.
Our ninth patient was a 13 old year girl with
Down’s syndrome and a non-restrictive ventricular
septal defect. Prior to treatment with Bosentan, she
was passive and difficult to mobilize. After 6 months
follow-up, her parents reported a marked improvement
in her mood and initiative. In contrast to her stopping
multiple times with blue lips when climbing the small
hill to their mountain cabin, she was now able to
walk this distance rapidly with a pink-lipped smile.
Measurement of mean saturations of oxygen over 24
hours declined from 97.3% to 94.7%, albeit that night
time saturations improved from 85.3% to 88.1%.
Saturations of oxygen
Baseline mean levels ranged from 85% to 95%.
Patients with normal baseline saturations at rest
demonstrated significant desaturations during exercise.
Six hours of sleep, including night time saturations,
were analysed as a separate parameter. Group values
before and after 12 months of treatment are pre-
sented in Table 3, and the individual values of the
mean saturations over 24 hours are shown in Figure 2.
The average of 24 hour mean heart rate at baseline
was 84.2 plus or minus 12.2, and at 12 months was
80.8 plus or minus 12.0 beats per minute (p is equal
to 0.12). The saturations of oxygen improved in one
patient, were stable in seven, and declined in six.
Changes were minor, except for the third and sev-
enth patients. We could not identify any special
characteristics in these two patients, and no relation-
ship could be found between changes in saturation
and symptoms. Even with the exclusion of the sec-
ond patient, who developed nasal congestion, differ-
ences in saturations over 24 hours were significant
(p is equal to 0.05).
The saturations showed large variations within
each registration. The mean value of the difference
between the 5th and 95th percentile from all record-
ings was 10.7% plus or minus 5.9. This marker of
variation was similar at baseline and 12 months (p is
equal to 0.7). In most patients, significant resting
variation was observed. Figure 3 shows the variation
in mean and median saturations from standardized
30 minutes resting measurements in our fourth
patient during 8 consecutive days.
Exercise testing
We were able to complete treadmill testing in 6
patients. The individual values of peak uptake of oxy-
gen are shown in Figure 4, indicating a gradual fall
in exercise tolerance during the period of study. The
mean reduction of peak uptake adjusted for age was
7.7 plus or minus 6.9 millilitres per 0.67 kilo (p is
equal to 0.045). All treadmill tests were conducted to
volitional fatigue, and we failed to register any sig-
nificant falls in blood pressure, signs of ischaemia, or
arrhythmias. Saturations of oxygen at end exercise
declined to levels below the reliability of our equip-
ment, and could not be compared. Submaximal exer-
cise capacity also showed a trend to decline as
represented by the uptake at 80% of maximal heart
rate. Mean reduction was 15.3 plus or minus 15.7
millilitres per 0.67 kilo (p is equal to 0.06). Mean
Table 2. Reported performance before and after 12 months of
therapy with Bosentan. Values represent symptom score as mean
plus or minus standard deviation.
Baseline 12 months p-value
School participation 2,8 (0,9) 3,2 (1,0) 0,165
Walking flat surface 2,9 (0,8) 3,5 (0,5) 0,014
Running/jogging 2,0 (0,9) 2,4 (1,4) 0,315
Walking stairs 2,6 (0,8) 3,1 (0,7) 0,082
Tiredness 2,5 (1,0) 3,4 (0,9) 0,001
Total score 12,8 (3,8) 15,5 (4,1) 0,009
Table 3. Group oxygen saturation variables before and after 12
months of Bosentan treatment. Scores are for the mean plus or
minus standard deviations.
Baseline 12 months p-value
24 hours mean 90,7 (6,8) 89,0 (6,0) 0,031
5th centile 24 hours 85,1 (11,0) 83,3 (7,9) 0,27
95th centile 24 hours 94,6 (4,9) 93,3 (5,2) 0,003
6 hours night, mean 91,1 (6,6) 88,0 (6,2) 0,08
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slope of minute ventilation plotted against uptake
increased with 12.2 plus or minus 7.4 from above
normal levels at baseline (p is equal to 0.01). A trend
towards increased slope of minute ventilation to pro-
duction of carbon dioxide was found. The mean incre-
ment was 7.1 plus or minus 7.4 (p is equal to 0.06).
Blood tests
All patients had blood tests performed at all assess-
ments in addition to the monthly control of hepatic
enzymes. No significant change was seen in levels of
haemoglobin or haematocrit from baseline to 12
months follow-up. A mean rise in serum uric acid of
25 plus or minus 24 units was seen during the same
period (p is equal to 0.05). Values of Nt-proANP were
normal in all but the second and eighth patients,
who had moderately elevated values, ranging from
1800 to 2200 throughout the period of study.
Echocardiography
Because of the varying anatomy, no parameter was
found suitable for comparison on a group level. No
definite echocardiographic changes were registered
in any individual patient.
Discussion
This is, to our knowledge, the first study over the
intermediate term of treatment with Bosentan
addressing specifically children and adolescents with
the Eisenmenger syndrome. We registered a small
but significant fall in saturations of oxygen, and
reduced exercise tolerance in a subset. Despite this,
the patients reported symptomatic relief.
With regard to saturations of oxygen, invasive
measurements of pulmonary vascular resistance
employing the Fick method may be imprecise, and
the findings during general anaesthesia do not nec-
essarily reflect the natural condition of the patient.
Besides, cardiac catheterization is not without risks
in this group of patients. We thus chose to use non-
invasive endpoints, with saturation as the most
important. The primary hypothesis was that, in the
presence of a reversed systemic-to-pulmonary shunt,
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Individual values of mean 24 hour oxygen saturation at baseline,
and after 6 and 12 months of treatment.
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a reduction of pulmonary vascular resistance should
decrease the degree of desaturation, either at rest in
hypoxaemic patients, or during physical activity in
those who were normoxaemic. There is no gold stan-
dard for measurements in this situation. Traditionally,
saturations have been registered in the supine position
for a short period. As demonstrated in Figure 3, this
may be imprecise and unreliable. In analogy with
measurements of blood pressure taken over 24 hours,
we believe that a long-time recording increases the
representivity and validity of the findings. A major
advantage with the chosen equipment is the possi-
bility of computerized registration and calculation of
data. Several mechanisms may account for the observed
decline in saturations after 12 months of treatment
with Bosentan. Symptomatic improvement resulting
in increased physical activity could lead to more fre-
quent or longer lasting desaturations. Registrations,
however, were done in hospital at stable and low levels
of activity, and the value of the fifth centile for satu-
ration remained unchanged. In a recently published
randomised controlled trial of Bosentan in adults
with Eisenmenger’s syndrome, a borderline significant
reduction in systemic vascular resistance was
observed.17 We suggest that systemic vasodilation is
the most likely explanation for the small but statis-
tically significant fall in saturation observed in our
patients. This is supported by the reduction of dias-
tolic blood pressure. Measurements taken at night
time show a less pronounced decline than the values
for the 95th centile. There were individual variations,
but preservation of cerebrovascular saturation during
sleep, and increased cardiac output, could be a mech-
anism of the significant reduction of tiredness.
With regard to symptoms, our study differs
markedly from other studies in including patients
almost exclusively in functional class 2 of the system
of the New York Heart Association. The improved
functioning reported by the patients and their parents
may, of course, represent a placebo effect. Such a mech-
anism, however, would be expected to fade away with
time, and in several cases, we registered a marked and
long-lasting improvement. The relief of symptoms
in spite of lower saturations of oxygen may be explained
by improvement of cardiac output, following reduction
of both systemic and pulmonary vascular resistances.
Improved cardiac function and increased coronary arte-
rial flow by antagonists of endothelin receptors are
described in experimental models.18–20 We did not
include measurements of cardiac output in this study.
Exercise testing, with measurement of uptake of
oxygen, is validated in children and regularly used as
a core parameter of cardiopulmonary function in our
department.16 It is also useful for the assessment of
pulmonary hypertension.21 In our study, significant
improvement of flat walking distance was reported,
which implies improved submaximal exercise toler-
ance. This is difficult to integrate with the decline in
peak uptake of oxygen. One explanation may be that
a reduced systemic vascular resistance improves cardiac
output at submaximal exercise, while increased desat-
uration becomes a limiting factor at higher intensity
levels. Increased ventilation perfusion mismatch during
maximal exercise may also be a factor of importance.
Levels of uric acid in the serum correlate with
severity and survival in idiopathic pulmonary hyper-
tension, possibly reflecting peripheral oxygenation
of the tissues.22 In our study, such levels increased,
but values of haemoglobin and haematocrit were stable,
supporting preserved oxygenation.
Our study has the general limitations of uncon-
trolled observational studies. Eisenmenger’s syndrome
is assumed to be a stable condition at this age. All
patients were clinically stable during their last year
before starting treatment. This makes the use of the
patients as their own controls more reliable. Stable low
values of natriuretic peptides strongly contradict devel-
opment of heart failure. We cannot excluded com-
pletely, however, the possibility that deterioration may
have been prevented by treatment with Bosentan.
The outcome in our study may have become affected
by a deviant treatment response in patients with
genetic predisposition for development of pulmonary
hypertension. This may apply particularly for our 2
patients with atrial septal defects, and for the 5
patients with Down’s syndrome, who represent a
large proportion of our cohort. The distribution,
nonetheless, is probably representative for the occur-
rence of Eisenmenger’s syndrome in childhood. 
The most important limitation of the study is our
failure to measure cardiac output.
Other reports of treatment with Bosentan in pul-
monary arterial hypertension are almost uniformly
positive. Previous uncontrolled studies, including both
patients with and without Eisenmenger’s physiology,
report positive clinical and hemodynamic effects at
16 weeks.9,12,14 Recent small-scale, uncontrolled tri-
als in adults with Eisenmenger’s syndrome demon-
strated improvement in saturations of oxygen, and
in echocardiographic, haemodynamic, and exercise
parameters at 16 weeks.10,11 Our findings are also
partly in conflict with the findings of Apostolopoulou
et al. in younger patients,9 albeit that the different
methods for measuring saturations of oxygen must
be kept in mind. The first randomized trial of
Bosentan in adults with Eisenmenger’s syndrome
demonstrated non-inferiority of the primary end
point of saturations of oxygen, and a slight improve-
ment of 6 minutes walk test after 16 weeks of treat-
ment.17 Placebo-controlled short-term studies will,
however, only answer some of the questions related
to treatment of this complex group of patients, and
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our protocol was designed to study the effects after
one year. In contrast to other patients with pulmonary
hypertension, patients with Eisenmenger’s syndrome
could be re-exposed to pulmonary hyperflow in case
of therapeutic success. We emphasize, therefore, the
need for studies of long-term outcome.
In conclusion, our data suggest that saturations of
oxygen in mildly symptomatic children and adoles-
cents with Eisenmenger’s physiology are not improved
by treatment with Bosentan as judged by follow-up
at one year. In contrast to the original hypothesis,
our findings indicate that giving Bosentan in children
with Eisenmenger’s syndrome does not cause a selec-
tive reduction in pulmonary vascular resistance. Our
findings may indicate, nonetheless, that there is
symptomatic improvement. A possible explanation
may be improved cardiac output, following a fall also
in the systemic vascular resistance. For a proper under-
standing of the complex haemodynamic alterations,
it is necessary to address ventilation-perfusion mis-
match and cardiac output, in addition to vascular
resistances and clinical findings. Our study does not
permit conclusions to be drawn regarding the long
term therapeutic benefit from Bosentan as given to
young patients with Eisenmenger’s syndrome.
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